[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fyvcFuEpgDU4kO2m66bp9w22mdyNpeBQT1-rW8AN6hSQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":38,"phaseBuckets":88,"rows":95},"Shandong University",[4,6],"Shandong University of Traditional Chinese Medicine",292,false,32,21,40516793,31,147,[15,17,20,23,26,29,32,35],{"name":16,"count":12},"Helicobacter Pylori Infection",{"name":18,"count":19},"Immune Thrombocytopenia",29,{"name":21,"count":22},"Artificial Intelligence",14,{"name":24,"count":25},"Gastric Intestinal Metaplasia",11,{"name":27,"count":28},"Helicobacter Pylori",10,{"name":30,"count":31},"Colorectal Neoplasms",8,{"name":33,"count":34},"Irritable Bowel Syndrome",7,{"name":36,"count":37},"Bowel Preparation",6,[39,44,49,54,59,64,68,73,78,83],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT05023915","A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP","2021-08-21","dexamethasone",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06440824","A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin","2025-06-01","Romiplostim N01",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT06723197","Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication","2025-10-01","vonoprazan+amoxicillin",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06649422","Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study","2025-12","Blinatumomab",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT04716686","Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma","2025-12-31","Niraparib",{"nctId":65,"briefTitle":66,"date":62,"intervention":67},"NCT07046988","Population Pharmacokinetics of Terbinafine in Children With Tinea Capitis","Terbinafine",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT06913374","The Study of Different Cycles of High-dose Dexamethasone in the Treatment of ITP","2026-05-30","Dexamethasone",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06251947","Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen","2026-06","Efbemalenograstim Alfa",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT04872660","Efficacy and Safety of Gushen Antai Pill on Ongoing Pregnancy Rate in Women With Normal Ovarian Reserve Undergoing IVF-ET","2026-06-30","Gushen Antai Pill",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT06076200","Population Pharmacokinetic of Piperacillin\u002FTazobactam in Maternal and Neonatal Populations","2026-07-01","Piperacillin Sodium and Tazobactam Sodium for",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,125,148,172,195,213,403,444,462,488,506,533,551,574,592,622,640,658,676,694,712,734,760,792,812,839,857,883,904,926,952,970,1032,1083,1132,1170,1212,1238,1264,1290,1315,1337,1370,1404,1432,1454,1476,1516,1538,1560,1582,1604,1641,1663,1685,1707,1731,1749,1772,1797,1822,1840,1867,1885,1903,1921,1939,1965,1983,2007,2025,2051,2069,2087,2111,2129,2155,2173,2198,2216,2234,2257,2283,2301,2330,2348,2366,2384,2402,2420,2438,2456,2474,2500,2518,2544,2562,2586,2604,2627,2651,2675,2700,2718,2736,2754,2772,2790,2838,2874,2899,2917,2941,2964,2982,3000,3018,3036,3054,3072,3090,3124,3149,3167,3185,3208,3226,3252,3270,3288,3306,3324,3342,3365,3388,3415,3433,3451,3469,3493,3519,3545,3568,3586,3609,3632,3654,3678,3724,3752,3776,3799,3824,3849,3867,3891,3916,3943,3961,3979,4004,4032,4050,4068,4086,4104,4122,4146,4164,4187,4212,4230,4248,4270,4293,4319,4337,4355,4382,4400,4421,4447,4473,4491,4509,4534,4552,4570,4591,4613,4637,4661,4684,4702,4725,4743,4769,4787,4810,4828,4851,4876,4902],{"intervention":97,"totalTrials":98,"cells":99},"H. pylori eradication",1,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":109,"NA":123},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[],{"trials":106,"activeCount":102},[],{"trials":108,"activeCount":102},[],{"trials":110,"activeCount":98,"soonestReadout":116},[111],{"nctId":112,"briefTitle":113,"status":114,"phases":115,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":122},"NCT02933229","The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study","NOT_YET_RECRUITING",[93],"2031-10","2016-10",300,[27,120,121],"the Operative Link on Gastric Intestinal Metaplasia","Operative Link on Gastric Intestinal Assessment",[97],{"trials":124,"activeCount":102},[],{"intervention":82,"totalTrials":98,"cells":126},{"EARLY_PHASE1":127,"PHASE1":129,"PHASE2":131,"PHASE3":133,"PHASE4":135,"NA":146},{"trials":128,"activeCount":102},[],{"trials":130,"activeCount":102},[],{"trials":132,"activeCount":102},[],{"trials":134,"activeCount":102},[],{"trials":136,"activeCount":98,"soonestReadout":81},[137],{"nctId":79,"briefTitle":80,"status":138,"phases":139,"primaryCompletion":81,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":145},"RECRUITING",[93],"2026-12-30","2021-06-15",800,[144],"Infertility, Female",[82],{"trials":147,"activeCount":102},[],{"intervention":149,"totalTrials":98,"cells":150},"Talniflumate",{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":157,"PHASE4":159,"NA":170},{"trials":152,"activeCount":102},[],{"trials":154,"activeCount":102},[],{"trials":156,"activeCount":102},[],{"trials":158,"activeCount":102},[],{"trials":160,"activeCount":98,"soonestReadout":165},[161],{"nctId":162,"briefTitle":163,"status":114,"phases":164,"primaryCompletion":165,"completion":165,"start":47,"enrollment":166,"conditions":167,"interventions":169},"NCT06777537","Neoadjuvant Chemotherapy with or Without Talniflumate for the Treatment of Breast Cancer",[93],"2030-12-01",200,[168],"Breast Cancer",[149],{"trials":171,"activeCount":102},[],{"intervention":53,"totalTrials":98,"cells":173},{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":178,"PHASE3":180,"PHASE4":182,"NA":193},{"trials":175,"activeCount":102},[],{"trials":177,"activeCount":102},[],{"trials":179,"activeCount":102},[],{"trials":181,"activeCount":102},[],{"trials":183,"activeCount":98,"soonestReadout":52},[184],{"nctId":50,"briefTitle":51,"status":138,"phases":185,"primaryCompletion":52,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":191},[93],"2025-11-30","2024-12-10",330,[190],"HELICOBACTER PYLORI INFECTIONS",[53,192],"vonoprazan+amoxicillin+tetracycline+bismuth",{"trials":194,"activeCount":102},[],{"intervention":192,"totalTrials":98,"cells":196},{"EARLY_PHASE1":197,"PHASE1":199,"PHASE2":201,"PHASE3":203,"PHASE4":205,"NA":211},{"trials":198,"activeCount":102},[],{"trials":200,"activeCount":102},[],{"trials":202,"activeCount":102},[],{"trials":204,"activeCount":102},[],{"trials":206,"activeCount":98,"soonestReadout":52},[207],{"nctId":50,"briefTitle":51,"status":138,"phases":208,"primaryCompletion":52,"completion":186,"start":187,"enrollment":188,"conditions":209,"interventions":210},[93],[190],[53,192],{"trials":212,"activeCount":102},[],{"intervention":72,"totalTrials":214,"cells":215},18,{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":275,"PHASE4":346,"NA":395},{"trials":217,"activeCount":102},[],{"trials":219,"activeCount":102},[],{"trials":221,"activeCount":98,"soonestReadout":42},[222,235,245,253,265],{"nctId":223,"briefTitle":224,"status":225,"phases":226,"primaryCompletion":227,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":233},"NCT01965626","A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITP","COMPLETED",[91],"2018-05","2019-05","2016-02-01",96,[232],"Thrombocytopenia",[234,72],"Oseltamivir",{"nctId":236,"briefTitle":237,"status":238,"phases":239,"primaryCompletion":240,"start":241,"enrollment":102,"conditions":242,"interventions":243},"NCT01976195","High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP","WITHDRAWN",[91],"2014-12","2013-10",[18],[72,244],"Thalidomide",{"nctId":40,"briefTitle":41,"status":246,"phases":247,"primaryCompletion":42,"completion":248,"start":42,"enrollment":249,"conditions":250,"interventions":251},"ACTIVE_NOT_RECRUITING",[91],"2026-01-31",106,[18],[43,252],"diammonium glycyrrhizinate enteric-coated",{"nctId":254,"briefTitle":255,"status":256,"phases":257,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":263},"NCT03033199","Clinical Trial of Gut Microbiota in the Management of Immune Thrombocytopenia","UNKNOWN",[91],"2018-02","2018-08","2017-01",60,[18],[264,72],"Probiotic Agent",{"nctId":266,"briefTitle":267,"status":225,"phases":268,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":273,"interventions":274},"NCT02153060","An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP)",[91],"2015-01","2015-08","2014-05",58,[18],[72,72],{"trials":276,"activeCount":98,"soonestReadout":71},[277,287,298,310,320,329,336],{"nctId":278,"briefTitle":279,"status":238,"phases":280,"primaryCompletion":240,"start":281,"enrollment":102,"conditions":282,"interventions":285},"NCT01882127","All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)",[92],"2013-02",[283,284],"Purpura","Idiopathic Thrombocytopenic Purpura",[286,72],"All-Trans Retinoid Acid",{"nctId":288,"briefTitle":289,"status":256,"phases":290,"primaryCompletion":291,"completion":292,"start":293,"enrollment":166,"conditions":294,"interventions":296},"NCT03252457","Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP",[92],"2020-12-01","2021-12-01","2018-09-01",[295,18],"Purpura, Thrombocytopenic, Idiopathic",[297,72],"Decitabine",{"nctId":299,"briefTitle":300,"status":256,"phases":301,"primaryCompletion":292,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":307},"NCT03692754","Atorvastatin in Management of Newly Diagnosed ITP",[91,92],"2023-12-01","2021-11-01",30,[18,306],"Purpura, Thrombocytopenic",[308,309,72],"Atorvastatin 20mg","Atorvastatin 10mg",{"nctId":311,"briefTitle":312,"status":225,"phases":313,"primaryCompletion":314,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":318},"NCT02351622","Caffeic Acid Tablets as a Second-line Therapy for ITP",[92],"2013-12","2012-09",103,[18],[319,72],"Caffeic acid",{"nctId":321,"briefTitle":322,"status":238,"phases":323,"primaryCompletion":324,"completion":241,"start":325,"enrollment":102,"conditions":326,"interventions":327},"NCT01734057","Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)",[92],"2013-07","2012-07",[283,284],[328,72],"recombinant human thrombopoietin (rhTPO); rituximab",{"nctId":69,"briefTitle":70,"status":114,"phases":330,"primaryCompletion":71,"completion":331,"start":332,"enrollment":333,"conditions":334,"interventions":335},[91,92],"2027-05-30","2025-05-01",118,[232],[72,72],{"nctId":337,"briefTitle":338,"status":225,"phases":339,"primaryCompletion":340,"completion":341,"start":325,"enrollment":342,"conditions":343,"interventions":344},"NCT01734044","rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP",[92],"2014-07","2014-11",158,[283,284],[345,72],"recombinant human thrombopoietin (rhTPO); dexamethasone",{"trials":347,"activeCount":102},[348,356,366,375,385],{"nctId":349,"briefTitle":350,"status":238,"phases":351,"primaryCompletion":352,"completion":352,"start":353,"enrollment":102,"conditions":354,"interventions":355},"NCT02642380","Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP)",[93],"2018-11","2015-11",[18],[72,72],{"nctId":357,"briefTitle":358,"status":256,"phases":359,"primaryCompletion":360,"completion":361,"start":362,"enrollment":261,"conditions":363,"interventions":364},"NCT04094805","A Multicenter Randomized Study of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP",[93],"2021-03-01","2021-10-01","2020-10-01",[18],[365,72],"Rocaltrol",{"nctId":367,"briefTitle":368,"status":256,"phases":369,"primaryCompletion":370,"completion":370,"start":371,"enrollment":304,"conditions":372,"interventions":373},"NCT03998982","Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP",[93],"2021-06-10","2019-06-25",[18],[374,72],"Glycyrrhetinic Acid",{"nctId":376,"briefTitle":377,"status":225,"phases":378,"primaryCompletion":379,"completion":380,"start":381,"enrollment":382,"conditions":383,"interventions":384},"NCT02556814","Caffeic Acid Combining High-dose Dexamethasone in Management of ITP",[93],"2018-03","2018-10","2015-09",214,[18],[319,72],{"nctId":386,"briefTitle":387,"status":225,"phases":388,"primaryCompletion":271,"completion":389,"start":390,"enrollment":391,"conditions":392,"interventions":393},"NCT01356511","High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)",[93],"2015-03","2010-09",261,[295],[394,72],"Prednisone",{"trials":396,"activeCount":102},[397],{"nctId":398,"briefTitle":399,"status":256,"phases":400,"primaryCompletion":360,"completion":361,"start":362,"enrollment":261,"conditions":401,"interventions":402},"NCT04320225","Connection Between Vitamin D Level and the Efficacy of Dexamethasone in Immune Thrombocytopenia",[],[18],[72],{"intervention":404,"totalTrials":405,"cells":406},"Recombinant Human Thrombopoietin",3,{"EARLY_PHASE1":407,"PHASE1":409,"PHASE2":411,"PHASE3":413,"PHASE4":440,"NA":442},{"trials":408,"activeCount":102},[],{"trials":410,"activeCount":102},[],{"trials":412,"activeCount":102},[],{"trials":414,"activeCount":98,"soonestReadout":47},[415,421,428],{"nctId":45,"briefTitle":46,"status":114,"phases":416,"primaryCompletion":47,"completion":186,"start":417,"enrollment":261,"conditions":418,"interventions":420},[92],"2024-06-01",[419],"CTIT-Chemotherapy Induced Thrombocytopenia",[48,404],{"nctId":422,"briefTitle":423,"status":225,"phases":424,"primaryCompletion":269,"completion":269,"start":271,"enrollment":425,"conditions":426,"interventions":427},"NCT02139501","An Investigation of rhTPO With Different Frequencies in the Management of ITP",[92],48,[18],[404],{"nctId":429,"briefTitle":430,"status":256,"phases":431,"primaryCompletion":432,"completion":433,"start":434,"enrollment":435,"conditions":436,"interventions":437},"NCT03492515","Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia",[92],"2020-05-01","2022-05-01","2018-05-01",90,[18],[438,439],"recombinant human thrombopoietin","Platelet Concentrate",{"trials":441,"activeCount":102},[],{"trials":443,"activeCount":102},[],{"intervention":48,"totalTrials":98,"cells":445},{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":452,"PHASE4":458,"NA":460},{"trials":447,"activeCount":102},[],{"trials":449,"activeCount":102},[],{"trials":451,"activeCount":102},[],{"trials":453,"activeCount":98,"soonestReadout":47},[454],{"nctId":45,"briefTitle":46,"status":114,"phases":455,"primaryCompletion":47,"completion":186,"start":417,"enrollment":261,"conditions":456,"interventions":457},[92],[419],[48,404],{"trials":459,"activeCount":102},[],{"trials":461,"activeCount":102},[],{"intervention":463,"totalTrials":98,"cells":464},"Progesterone-modified natural cycle preparation for frozen embryo transfer",{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":469,"PHASE3":471,"PHASE4":484,"NA":486},{"trials":466,"activeCount":102},[],{"trials":468,"activeCount":102},[],{"trials":470,"activeCount":102},[],{"trials":472,"activeCount":98,"soonestReadout":477},[473],{"nctId":474,"briefTitle":475,"status":138,"phases":476,"primaryCompletion":477,"completion":478,"start":479,"enrollment":480,"conditions":481,"interventions":482},"NCT06644794","Progesterone-modified Natural Cycle for FET",[92],"2027-09-10","2028-12-01","2025-03-05",336,[144],[463,483],"Hormone replacement therapy cycle preparation for frozen embryo transfer",{"trials":485,"activeCount":102},[],{"trials":487,"activeCount":102},[],{"intervention":483,"totalTrials":98,"cells":489},{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":494,"PHASE3":496,"PHASE4":502,"NA":504},{"trials":491,"activeCount":102},[],{"trials":493,"activeCount":102},[],{"trials":495,"activeCount":102},[],{"trials":497,"activeCount":98,"soonestReadout":477},[498],{"nctId":474,"briefTitle":475,"status":138,"phases":499,"primaryCompletion":477,"completion":478,"start":479,"enrollment":480,"conditions":500,"interventions":501},[92],[144],[463,483],{"trials":503,"activeCount":102},[],{"trials":505,"activeCount":102},[],{"intervention":507,"totalTrials":98,"cells":508},"High-Dose Dexamethasone Combined with Orelabrutinib",{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":515,"PHASE4":529,"NA":531},{"trials":510,"activeCount":102},[],{"trials":512,"activeCount":102},[],{"trials":514,"activeCount":102},[],{"trials":516,"activeCount":98,"soonestReadout":521},[517],{"nctId":518,"briefTitle":519,"status":138,"phases":520,"primaryCompletion":521,"completion":522,"start":523,"enrollment":524,"conditions":525,"interventions":527},"NCT07559331","High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia",[92],"2027-04-08","2028-12-31","2026-04-08",86,[526],"Primary Immune Thrombocytopenia (ITP)",[507,528],"High-Dose Dexamethasone Combined with Placebo",{"trials":530,"activeCount":102},[],{"trials":532,"activeCount":102},[],{"intervention":528,"totalTrials":98,"cells":534},{"EARLY_PHASE1":535,"PHASE1":537,"PHASE2":539,"PHASE3":541,"PHASE4":547,"NA":549},{"trials":536,"activeCount":102},[],{"trials":538,"activeCount":102},[],{"trials":540,"activeCount":102},[],{"trials":542,"activeCount":98,"soonestReadout":521},[543],{"nctId":518,"briefTitle":519,"status":138,"phases":544,"primaryCompletion":521,"completion":522,"start":523,"enrollment":524,"conditions":545,"interventions":546},[92],[526],[507,528],{"trials":548,"activeCount":102},[],{"trials":550,"activeCount":102},[],{"intervention":63,"totalTrials":98,"cells":552},{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":568,"PHASE4":570,"NA":572},{"trials":554,"activeCount":102},[],{"trials":556,"activeCount":102},[],{"trials":558,"activeCount":98,"soonestReadout":62},[559],{"nctId":60,"briefTitle":61,"status":138,"phases":560,"primaryCompletion":62,"completion":561,"start":562,"enrollment":563,"conditions":564,"interventions":567},[91],"2026-12-31","2021-06-01",83,[565,566],"Endometrial Carcinoma","Serous Carcinoma",[63],{"trials":569,"activeCount":102},[],{"trials":571,"activeCount":102},[],{"trials":573,"activeCount":102},[],{"intervention":252,"totalTrials":98,"cells":575},{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":580,"PHASE3":586,"PHASE4":588,"NA":590},{"trials":577,"activeCount":102},[],{"trials":579,"activeCount":102},[],{"trials":581,"activeCount":98,"soonestReadout":42},[582],{"nctId":40,"briefTitle":41,"status":246,"phases":583,"primaryCompletion":42,"completion":248,"start":42,"enrollment":249,"conditions":584,"interventions":585},[91],[18],[43,252],{"trials":587,"activeCount":102},[],{"trials":589,"activeCount":102},[],{"trials":591,"activeCount":102},[],{"intervention":593,"totalTrials":98,"cells":594},"Rifampin",{"EARLY_PHASE1":595,"PHASE1":597,"PHASE2":599,"PHASE3":616,"PHASE4":618,"NA":620},{"trials":596,"activeCount":102},[],{"trials":598,"activeCount":102},[],{"trials":600,"activeCount":98,"soonestReadout":605},[601],{"nctId":602,"briefTitle":603,"status":114,"phases":604,"primaryCompletion":605,"completion":606,"start":607,"enrollment":118,"conditions":608,"interventions":610},"NCT06917495","Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis",[91],"2027-12-31","2029-12-31","2025-04-05",[609],"Mild Spinal Tuberculosis",[593,611,612,613,614,615],"Isoniazid","Rifapentine","Moxifloxacin","Pyrazinamide","Ethambutol",{"trials":617,"activeCount":102},[],{"trials":619,"activeCount":102},[],{"trials":621,"activeCount":102},[],{"intervention":611,"totalTrials":98,"cells":623},{"EARLY_PHASE1":624,"PHASE1":626,"PHASE2":628,"PHASE3":634,"PHASE4":636,"NA":638},{"trials":625,"activeCount":102},[],{"trials":627,"activeCount":102},[],{"trials":629,"activeCount":98,"soonestReadout":605},[630],{"nctId":602,"briefTitle":603,"status":114,"phases":631,"primaryCompletion":605,"completion":606,"start":607,"enrollment":118,"conditions":632,"interventions":633},[91],[609],[593,611,612,613,614,615],{"trials":635,"activeCount":102},[],{"trials":637,"activeCount":102},[],{"trials":639,"activeCount":102},[],{"intervention":612,"totalTrials":98,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":652,"PHASE4":654,"NA":656},{"trials":643,"activeCount":102},[],{"trials":645,"activeCount":102},[],{"trials":647,"activeCount":98,"soonestReadout":605},[648],{"nctId":602,"briefTitle":603,"status":114,"phases":649,"primaryCompletion":605,"completion":606,"start":607,"enrollment":118,"conditions":650,"interventions":651},[91],[609],[593,611,612,613,614,615],{"trials":653,"activeCount":102},[],{"trials":655,"activeCount":102},[],{"trials":657,"activeCount":102},[],{"intervention":613,"totalTrials":98,"cells":659},{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":670,"PHASE4":672,"NA":674},{"trials":661,"activeCount":102},[],{"trials":663,"activeCount":102},[],{"trials":665,"activeCount":98,"soonestReadout":605},[666],{"nctId":602,"briefTitle":603,"status":114,"phases":667,"primaryCompletion":605,"completion":606,"start":607,"enrollment":118,"conditions":668,"interventions":669},[91],[609],[593,611,612,613,614,615],{"trials":671,"activeCount":102},[],{"trials":673,"activeCount":102},[],{"trials":675,"activeCount":102},[],{"intervention":614,"totalTrials":98,"cells":677},{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":688,"PHASE4":690,"NA":692},{"trials":679,"activeCount":102},[],{"trials":681,"activeCount":102},[],{"trials":683,"activeCount":98,"soonestReadout":605},[684],{"nctId":602,"briefTitle":603,"status":114,"phases":685,"primaryCompletion":605,"completion":606,"start":607,"enrollment":118,"conditions":686,"interventions":687},[91],[609],[593,611,612,613,614,615],{"trials":689,"activeCount":102},[],{"trials":691,"activeCount":102},[],{"trials":693,"activeCount":102},[],{"intervention":615,"totalTrials":98,"cells":695},{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":700,"PHASE3":706,"PHASE4":708,"NA":710},{"trials":697,"activeCount":102},[],{"trials":699,"activeCount":102},[],{"trials":701,"activeCount":98,"soonestReadout":605},[702],{"nctId":602,"briefTitle":603,"status":114,"phases":703,"primaryCompletion":605,"completion":606,"start":607,"enrollment":118,"conditions":704,"interventions":705},[91],[609],[593,611,612,613,614,615],{"trials":707,"activeCount":102},[],{"trials":709,"activeCount":102},[],{"trials":711,"activeCount":102},[],{"intervention":77,"totalTrials":98,"cells":713},{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":728,"PHASE4":730,"NA":732},{"trials":715,"activeCount":102},[],{"trials":717,"activeCount":102},[],{"trials":719,"activeCount":98,"soonestReadout":76},[720],{"nctId":74,"briefTitle":75,"status":138,"phases":721,"primaryCompletion":76,"completion":722,"start":723,"enrollment":563,"conditions":724,"interventions":727},[91],"2026-12","2024-04-15",[725,726],"Ovarian Cancer","Cervical Cancer",[77],{"trials":729,"activeCount":102},[],{"trials":731,"activeCount":102},[],{"trials":733,"activeCount":102},[],{"intervention":735,"totalTrials":98,"cells":736},"Shouhui Tongbian",{"EARLY_PHASE1":737,"PHASE1":750,"PHASE2":752,"PHASE3":754,"PHASE4":756,"NA":758},{"trials":738,"activeCount":98,"soonestReadout":743},[739],{"nctId":740,"briefTitle":741,"status":114,"phases":742,"primaryCompletion":743,"completion":744,"start":745,"enrollment":746,"conditions":747,"interventions":749},"NCT07066059","Study on the Efficacy and Safety of Shouhui Tongbian Capsules in Protecting Intestine During the Perioperative Period",[89],"2027-03-31","2027-07-31","2025-08-01",80,[748],"Perioperative Period",[735],{"trials":751,"activeCount":102},[],{"trials":753,"activeCount":102},[],{"trials":755,"activeCount":102},[],{"trials":757,"activeCount":102},[],{"trials":759,"activeCount":102},[],{"intervention":761,"totalTrials":762,"cells":763},"Anti-Infective Drugs",2,{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":770,"PHASE4":772,"NA":774},{"trials":765,"activeCount":102},[],{"trials":767,"activeCount":102},[],{"trials":769,"activeCount":102},[],{"trials":771,"activeCount":102},[],{"trials":773,"activeCount":102},[],{"trials":775,"activeCount":762,"soonestReadout":780},[776,785],{"nctId":777,"briefTitle":778,"status":138,"phases":779,"primaryCompletion":780,"completion":780,"start":781,"enrollment":118,"conditions":782,"interventions":784},"NCT06711562","Model-informed Individualized Treatment of Anti-infective Drugs",[],"2026-10-01","2024-10-12",[783],"Osteoarticular Infections",[761],{"nctId":786,"briefTitle":787,"status":138,"phases":788,"primaryCompletion":780,"completion":780,"start":781,"enrollment":118,"conditions":789,"interventions":791},"NCT06711575","Model-informed Individualized Treatment of Anti-Infective Drugs in Patients With Spinal Infections",[],[790],"Infectious Diseases of Spine",[761],{"intervention":67,"totalTrials":98,"cells":793},{"EARLY_PHASE1":794,"PHASE1":796,"PHASE2":798,"PHASE3":800,"PHASE4":802,"NA":804},{"trials":795,"activeCount":102},[],{"trials":797,"activeCount":102},[],{"trials":799,"activeCount":102},[],{"trials":801,"activeCount":102},[],{"trials":803,"activeCount":102},[],{"trials":805,"activeCount":98,"soonestReadout":62},[806],{"nctId":65,"briefTitle":66,"status":138,"phases":807,"primaryCompletion":62,"completion":808,"start":141,"enrollment":261,"conditions":809,"interventions":811},[],"2026-06-01",[810],"Tinea Capitis",[67],{"intervention":813,"totalTrials":98,"cells":814},"Metformin pretreatment before ovarian stimulation",{"EARLY_PHASE1":815,"PHASE1":817,"PHASE2":819,"PHASE3":821,"PHASE4":823,"NA":825},{"trials":816,"activeCount":102},[],{"trials":818,"activeCount":102},[],{"trials":820,"activeCount":102},[],{"trials":822,"activeCount":102},[],{"trials":824,"activeCount":102},[],{"trials":826,"activeCount":98,"soonestReadout":561},[827],{"nctId":828,"briefTitle":829,"status":138,"phases":830,"primaryCompletion":561,"completion":605,"start":831,"enrollment":832,"conditions":833,"interventions":837},"NCT06064669","Effect of Metformin on Healthy Live Birth in Women With Prediabetes",[94],"2024-02-22",988,[834,835,836],"Metformin","Prediabetes","In-Vitro Fertilization",[813,838],"Metformin pretreatment before endometrial preparation for frozen embryo transfer",{"intervention":838,"totalTrials":98,"cells":840},{"EARLY_PHASE1":841,"PHASE1":843,"PHASE2":845,"PHASE3":847,"PHASE4":849,"NA":851},{"trials":842,"activeCount":102},[],{"trials":844,"activeCount":102},[],{"trials":846,"activeCount":102},[],{"trials":848,"activeCount":102},[],{"trials":850,"activeCount":102},[],{"trials":852,"activeCount":98,"soonestReadout":561},[853],{"nctId":828,"briefTitle":829,"status":138,"phases":854,"primaryCompletion":561,"completion":605,"start":831,"enrollment":832,"conditions":855,"interventions":856},[94],[834,835,836],[813,838],{"intervention":858,"totalTrials":98,"cells":859},"Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib",{"EARLY_PHASE1":860,"PHASE1":862,"PHASE2":864,"PHASE3":866,"PHASE4":868,"NA":870},{"trials":861,"activeCount":102},[],{"trials":863,"activeCount":102},[],{"trials":865,"activeCount":102},[],{"trials":867,"activeCount":102},[],{"trials":869,"activeCount":102},[],{"trials":871,"activeCount":98,"soonestReadout":876},[872],{"nctId":873,"briefTitle":874,"status":138,"phases":875,"primaryCompletion":876,"completion":877,"start":878,"enrollment":879,"conditions":880,"interventions":882},"NCT05467189","Antineoplastic Drugs in Elderly Patients",[],"2028-03-30","2028-06-30","2021-01-01",500,[881],"Cancer",[858],{"intervention":87,"totalTrials":98,"cells":884},{"EARLY_PHASE1":885,"PHASE1":887,"PHASE2":889,"PHASE3":891,"PHASE4":893,"NA":895},{"trials":886,"activeCount":102},[],{"trials":888,"activeCount":102},[],{"trials":890,"activeCount":102},[],{"trials":892,"activeCount":102},[],{"trials":894,"activeCount":102},[],{"trials":896,"activeCount":98,"soonestReadout":86},[897],{"nctId":84,"briefTitle":85,"status":138,"phases":898,"primaryCompletion":86,"completion":561,"start":899,"enrollment":900,"conditions":901,"interventions":903},[],"2023-09-30",50,[902],"Early-Onset Neonatal Sepsis",[87],{"intervention":58,"totalTrials":98,"cells":905},{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":914,"NA":916},{"trials":907,"activeCount":102},[],{"trials":909,"activeCount":102},[],{"trials":911,"activeCount":102},[],{"trials":913,"activeCount":102},[],{"trials":915,"activeCount":102},[],{"trials":917,"activeCount":98,"soonestReadout":57},[918],{"nctId":55,"briefTitle":56,"status":114,"phases":919,"primaryCompletion":57,"completion":920,"start":921,"enrollment":922,"conditions":923,"interventions":925},[],"2027-12","2024-11-01",36,[924],"Leukemia, Lymphocytic, Acute, Adult",[58],{"intervention":927,"totalTrials":98,"cells":928},"Increase the frequency and extended infusion time of Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda) 4.5g",{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":935,"PHASE4":937,"NA":939},{"trials":930,"activeCount":102},[],{"trials":932,"activeCount":102},[],{"trials":934,"activeCount":102},[],{"trials":936,"activeCount":102},[],{"trials":938,"activeCount":102},[],{"trials":940,"activeCount":98,"soonestReadout":945},[941],{"nctId":942,"briefTitle":943,"status":138,"phases":944,"primaryCompletion":945,"completion":945,"start":946,"enrollment":947,"conditions":948,"interventions":950},"NCT06972537","A Study on the Infusion Regimen of Piperacillin-Tazobactam in Patients Aged 65 and Older With Pneumonia",[94],"2026-09-30","2024-07-24",42,[949],"Pneumonia",[927,951],"Extended Infusion Time of Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda), 4.5g",{"intervention":951,"totalTrials":98,"cells":953},{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":962,"NA":964},{"trials":955,"activeCount":102},[],{"trials":957,"activeCount":102},[],{"trials":959,"activeCount":102},[],{"trials":961,"activeCount":102},[],{"trials":963,"activeCount":102},[],{"trials":965,"activeCount":98,"soonestReadout":945},[966],{"nctId":942,"briefTitle":943,"status":138,"phases":967,"primaryCompletion":945,"completion":945,"start":946,"enrollment":947,"conditions":968,"interventions":969},[94],[949],[927,951],{"intervention":971,"totalTrials":972,"cells":973},"Metronidazole",4,{"EARLY_PHASE1":974,"PHASE1":976,"PHASE2":978,"PHASE3":980,"PHASE4":982,"NA":1030},{"trials":975,"activeCount":102},[],{"trials":977,"activeCount":102},[],{"trials":979,"activeCount":102},[],{"trials":981,"activeCount":102},[],{"trials":983,"activeCount":102},[984,994,1005,1021],{"nctId":985,"briefTitle":986,"status":256,"phases":987,"primaryCompletion":988,"completion":989,"start":990,"enrollment":249,"conditions":991,"interventions":992},"NCT05129176","Helicobacter Pylori First-line Treatment Containing Tetracycline in Patients Allergic to Penicillin",[93],"2022-07","2022-11","2021-11-23",[16],[993,971],"Levofloxacin",{"nctId":995,"briefTitle":996,"status":256,"phases":997,"primaryCompletion":998,"completion":999,"start":1000,"enrollment":1001,"conditions":1002,"interventions":1003},"NCT05135182","Helicobacter Pylori Rescue Treatment in Patients Allergic to Penicillin",[93],"2022-10","2022-12","2021-11-28",170,[16],[1004,971],"Furazolidone",{"nctId":1006,"briefTitle":1007,"status":225,"phases":1008,"primaryCompletion":1009,"completion":1010,"start":1011,"enrollment":1012,"conditions":1013,"interventions":1014},"NCT05049902","Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication",[93],"2023-05-30","2023-06-30","2021-09-21",1300,[16],[1015,1016,1017,971,1018,1019,1020],"Amoxicillin","Clarithromycin","Tetracycline","Bismuth Potassium Citrate","Colloidal Bismuth Pectin","Vonoprazan fumarate",{"nctId":1022,"briefTitle":1023,"status":256,"phases":1024,"primaryCompletion":1025,"completion":1026,"start":1027,"enrollment":1012,"conditions":1028,"interventions":1029},"NCT04901117","Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days",[93],"2023-06","2023-08","2021-06",[16],[1015,1016,1017,971,1018,1019,1020],{"trials":1031,"activeCount":102},[],{"intervention":1033,"totalTrials":972,"cells":1034},"Rituximab",{"EARLY_PHASE1":1035,"PHASE1":1037,"PHASE2":1039,"PHASE3":1041,"PHASE4":1069,"NA":1081},{"trials":1036,"activeCount":102},[],{"trials":1038,"activeCount":102},[],{"trials":1040,"activeCount":102},[],{"trials":1042,"activeCount":102},[1043,1052,1059],{"nctId":1044,"briefTitle":1045,"status":256,"phases":1046,"primaryCompletion":1047,"completion":360,"start":1048,"enrollment":166,"conditions":1049,"interventions":1050},"NCT03443570","Rituximab Combining Bortezomib Versus Rituximab in Management of ITP",[92],"2020-03-01","2018-03-01",[18,295],[1033,1051],"Bortezomib",{"nctId":1053,"briefTitle":1054,"status":238,"phases":1055,"primaryCompletion":269,"completion":1056,"start":271,"enrollment":102,"conditions":1057,"interventions":1058},"NCT02137681","A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant\u002FRelapsed Immune Thrombocytopenia （ITP）",[92],"2016-01",[18],[1033],{"nctId":1060,"briefTitle":1061,"status":225,"phases":1062,"primaryCompletion":314,"completion":1063,"start":1064,"enrollment":1065,"conditions":1066,"interventions":1067},"NCT01525836","rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP",[92],"2014-06","2011-05",123,[283,284],[1068,1033],"rituximab; recombinant human thrombopoietin",{"trials":1070,"activeCount":102},[1071],{"nctId":1072,"briefTitle":1073,"status":225,"phases":1074,"primaryCompletion":1075,"completion":1076,"start":1077,"enrollment":1078,"conditions":1079,"interventions":1080},"NCT03258866","The Study of Different Dose Rituximab in the Treatment of ITP",[93],"2015-12-31","2016-12-31","2010-01-01",62,[295,18],[1033,1033],{"trials":1082,"activeCount":102},[],{"intervention":1019,"totalTrials":972,"cells":1084},{"EARLY_PHASE1":1085,"PHASE1":1087,"PHASE2":1089,"PHASE3":1091,"PHASE4":1093,"NA":1130},{"trials":1086,"activeCount":102},[],{"trials":1088,"activeCount":102},[],{"trials":1090,"activeCount":102},[],{"trials":1092,"activeCount":102},[],{"trials":1094,"activeCount":102},[1095,1110,1114,1118],{"nctId":1096,"briefTitle":1097,"status":256,"phases":1098,"primaryCompletion":1099,"completion":1100,"start":1101,"enrollment":1102,"conditions":1103,"interventions":1105},"NCT03571230","Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.",[93],"2019-12-30","2020-01-30","2018-07-01",400,[16,1104],"Antimicrobial Susceptibility Testing",[1106,1107,1108,1019,1109],"two sensitive antibiotics","two antibiotics based on personal medication history","one proton pump inhibitor","two antibiotics for failed eradication",{"nctId":1006,"briefTitle":1007,"status":225,"phases":1111,"primaryCompletion":1009,"completion":1010,"start":1011,"enrollment":1012,"conditions":1112,"interventions":1113},[93],[16],[1015,1016,1017,971,1018,1019,1020],{"nctId":1022,"briefTitle":1023,"status":256,"phases":1115,"primaryCompletion":1025,"completion":1026,"start":1027,"enrollment":1012,"conditions":1116,"interventions":1117},[93],[16],[1015,1016,1017,971,1018,1019,1020],{"nctId":1119,"briefTitle":1120,"status":225,"phases":1121,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":1124,"conditions":1125,"interventions":1126},"NCT05431075","Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses",[93],"2024-02-01","2022-07-01",406,[16],[1015,1127,1128,1018,1019,1129],"Tetracycline tid","Tetracycline qid","Esomeprazole 20mg",{"trials":1131,"activeCount":102},[],{"intervention":1004,"totalTrials":405,"cells":1133},{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1138,"PHASE3":1140,"PHASE4":1142,"NA":1168},{"trials":1135,"activeCount":102},[],{"trials":1137,"activeCount":102},[],{"trials":1139,"activeCount":102},[],{"trials":1141,"activeCount":102},[],{"trials":1143,"activeCount":102},[1144,1155,1164],{"nctId":1145,"briefTitle":1146,"status":256,"phases":1147,"primaryCompletion":1148,"completion":1149,"start":1150,"enrollment":1151,"conditions":1152,"interventions":1153},"NCT04264663","Helicobacter Pylori Rescue Treatment Containing Tetracycline in Patients Allergic to Penicillin",[93],"2022-10-30","2022-12-30","2019-11-01",250,[16],[1004,1154],"Tinidazole",{"nctId":1156,"briefTitle":1157,"status":225,"phases":1158,"primaryCompletion":1159,"completion":1159,"start":1160,"enrollment":1161,"conditions":1162,"interventions":1163},"NCT03716622","A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication",[93],"2019-08-31","2018-07-31",350,[27],[1004,1016],{"nctId":995,"briefTitle":996,"status":256,"phases":1165,"primaryCompletion":998,"completion":999,"start":1000,"enrollment":1001,"conditions":1166,"interventions":1167},[93],[16],[1004,971],{"trials":1169,"activeCount":102},[],{"intervention":1171,"totalTrials":405,"cells":1172},"Lidocaine",{"EARLY_PHASE1":1173,"PHASE1":1175,"PHASE2":1177,"PHASE3":1179,"PHASE4":1181,"NA":1210},{"trials":1174,"activeCount":102},[],{"trials":1176,"activeCount":102},[],{"trials":1178,"activeCount":102},[],{"trials":1180,"activeCount":102},[],{"trials":1182,"activeCount":102},[1183,1193,1200],{"nctId":1184,"briefTitle":1185,"status":256,"phases":1186,"primaryCompletion":291,"completion":1187,"start":1188,"enrollment":900,"conditions":1189,"interventions":1191},"NCT04439786","Intravenous Infusion of Lidocaine in Colonoscopy",[93],"2020-12-31","2020-07-01",[1190],"Sedation",[1192],"lidocaine",{"nctId":1194,"briefTitle":1195,"status":256,"phases":1196,"primaryCompletion":291,"completion":1187,"start":1188,"enrollment":1197,"conditions":1198,"interventions":1199},"NCT04439773","Intravenous Infusion of Lidocaine in Gastroscopy",[93],130,[1190],[1171],{"nctId":1201,"briefTitle":1202,"status":256,"phases":1203,"primaryCompletion":1204,"completion":1205,"start":1206,"enrollment":1207,"conditions":1208,"interventions":1209},"NCT03996577","Intravenous Infusion of Lidocaine in ERCP",[93],"2019-10-15","2019-11-15","2019-05-15",40,[1190],[1171],{"trials":1211,"activeCount":102},[],{"intervention":1016,"totalTrials":405,"cells":1213},{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1218,"PHASE3":1220,"PHASE4":1222,"NA":1236},{"trials":1215,"activeCount":102},[],{"trials":1217,"activeCount":102},[],{"trials":1219,"activeCount":102},[],{"trials":1221,"activeCount":102},[],{"trials":1223,"activeCount":102},[1224,1228,1232],{"nctId":1156,"briefTitle":1157,"status":225,"phases":1225,"primaryCompletion":1159,"completion":1159,"start":1160,"enrollment":1161,"conditions":1226,"interventions":1227},[93],[27],[1004,1016],{"nctId":1006,"briefTitle":1007,"status":225,"phases":1229,"primaryCompletion":1009,"completion":1010,"start":1011,"enrollment":1012,"conditions":1230,"interventions":1231},[93],[16],[1015,1016,1017,971,1018,1019,1020],{"nctId":1022,"briefTitle":1023,"status":256,"phases":1233,"primaryCompletion":1025,"completion":1026,"start":1027,"enrollment":1012,"conditions":1234,"interventions":1235},[93],[16],[1015,1016,1017,971,1018,1019,1020],{"trials":1237,"activeCount":102},[],{"intervention":1015,"totalTrials":405,"cells":1239},{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1244,"PHASE3":1246,"PHASE4":1248,"NA":1262},{"trials":1241,"activeCount":102},[],{"trials":1243,"activeCount":102},[],{"trials":1245,"activeCount":102},[],{"trials":1247,"activeCount":102},[],{"trials":1249,"activeCount":102},[1250,1254,1258],{"nctId":1006,"briefTitle":1007,"status":225,"phases":1251,"primaryCompletion":1009,"completion":1010,"start":1011,"enrollment":1012,"conditions":1252,"interventions":1253},[93],[16],[1015,1016,1017,971,1018,1019,1020],{"nctId":1022,"briefTitle":1023,"status":256,"phases":1255,"primaryCompletion":1025,"completion":1026,"start":1027,"enrollment":1012,"conditions":1256,"interventions":1257},[93],[16],[1015,1016,1017,971,1018,1019,1020],{"nctId":1119,"briefTitle":1120,"status":225,"phases":1259,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":1124,"conditions":1260,"interventions":1261},[93],[16],[1015,1127,1128,1018,1019,1129],{"trials":1263,"activeCount":102},[],{"intervention":1018,"totalTrials":405,"cells":1265},{"EARLY_PHASE1":1266,"PHASE1":1268,"PHASE2":1270,"PHASE3":1272,"PHASE4":1274,"NA":1288},{"trials":1267,"activeCount":102},[],{"trials":1269,"activeCount":102},[],{"trials":1271,"activeCount":102},[],{"trials":1273,"activeCount":102},[],{"trials":1275,"activeCount":102},[1276,1280,1284],{"nctId":1006,"briefTitle":1007,"status":225,"phases":1277,"primaryCompletion":1009,"completion":1010,"start":1011,"enrollment":1012,"conditions":1278,"interventions":1279},[93],[16],[1015,1016,1017,971,1018,1019,1020],{"nctId":1022,"briefTitle":1023,"status":256,"phases":1281,"primaryCompletion":1025,"completion":1026,"start":1027,"enrollment":1012,"conditions":1282,"interventions":1283},[93],[16],[1015,1016,1017,971,1018,1019,1020],{"nctId":1119,"briefTitle":1120,"status":225,"phases":1285,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":1124,"conditions":1286,"interventions":1287},[93],[16],[1015,1127,1128,1018,1019,1129],{"trials":1289,"activeCount":102},[],{"intervention":1154,"totalTrials":762,"cells":1291},{"EARLY_PHASE1":1292,"PHASE1":1294,"PHASE2":1296,"PHASE3":1298,"PHASE4":1300,"NA":1313},{"trials":1293,"activeCount":102},[],{"trials":1295,"activeCount":102},[],{"trials":1297,"activeCount":102},[],{"trials":1299,"activeCount":102},[],{"trials":1301,"activeCount":102},[1302,1306],{"nctId":1145,"briefTitle":1146,"status":256,"phases":1303,"primaryCompletion":1148,"completion":1149,"start":1150,"enrollment":1151,"conditions":1304,"interventions":1305},[93],[16],[1004,1154],{"nctId":1307,"briefTitle":1308,"status":256,"phases":1309,"primaryCompletion":998,"completion":999,"start":1150,"enrollment":1151,"conditions":1310,"interventions":1311},"NCT04122287","Helicobacter Pylori First-line Treatment in Patients Allergic to Penicillin",[93],[16],[993,1312],"tinidazole",{"trials":1314,"activeCount":102},[],{"intervention":993,"totalTrials":762,"cells":1316},{"EARLY_PHASE1":1317,"PHASE1":1319,"PHASE2":1321,"PHASE3":1323,"PHASE4":1325,"NA":1335},{"trials":1318,"activeCount":102},[],{"trials":1320,"activeCount":102},[],{"trials":1322,"activeCount":102},[],{"trials":1324,"activeCount":102},[],{"trials":1326,"activeCount":102},[1327,1331],{"nctId":985,"briefTitle":986,"status":256,"phases":1328,"primaryCompletion":988,"completion":989,"start":990,"enrollment":249,"conditions":1329,"interventions":1330},[93],[16],[993,971],{"nctId":1307,"briefTitle":1308,"status":256,"phases":1332,"primaryCompletion":998,"completion":999,"start":1150,"enrollment":1151,"conditions":1333,"interventions":1334},[93],[16],[993,1312],{"trials":1336,"activeCount":102},[],{"intervention":1338,"totalTrials":762,"cells":1339},"Huaier Granule",{"EARLY_PHASE1":1340,"PHASE1":1342,"PHASE2":1344,"PHASE3":1346,"PHASE4":1348,"NA":1368},{"trials":1341,"activeCount":102},[],{"trials":1343,"activeCount":102},[],{"trials":1345,"activeCount":102},[],{"trials":1347,"activeCount":102},[],{"trials":1349,"activeCount":102},[1350,1359],{"nctId":1351,"briefTitle":1352,"status":256,"phases":1353,"primaryCompletion":1354,"start":1355,"enrollment":118,"conditions":1356,"interventions":1358},"NCT02615457","Huaier Granule in Treating Women With Triple Negative Breast Cancer",[93],"2025-10","2015-10",[1357],"Triple Negative Breast Cancer",[1338],{"nctId":1360,"briefTitle":1361,"status":256,"phases":1362,"primaryCompletion":1354,"completion":1354,"start":1355,"enrollment":166,"conditions":1363,"interventions":1364},"NCT02627248","Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery",[93],[168],[1338,1365,1366,1367],"Epirubicin","Docetaxel","Cyclophosphamide",{"trials":1369,"activeCount":102},[],{"intervention":1371,"totalTrials":762,"cells":1372},"rabeprazole, amoxicillin, tetracycline, furazolidone",{"EARLY_PHASE1":1373,"PHASE1":1375,"PHASE2":1377,"PHASE3":1379,"PHASE4":1381,"NA":1402},{"trials":1374,"activeCount":102},[],{"trials":1376,"activeCount":102},[],{"trials":1378,"activeCount":102},[],{"trials":1380,"activeCount":102},[],{"trials":1382,"activeCount":102},[1383,1393],{"nctId":1384,"briefTitle":1385,"status":256,"phases":1386,"primaryCompletion":1159,"completion":1387,"start":1388,"enrollment":1389,"conditions":1390,"interventions":1391},"NCT03658733","A Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection",[93],"2019-10-31","2018-12-15",120,[16],[1392,1371],"esomeprazole, amoxicillin, tetracycline, furazolidone",{"nctId":1394,"briefTitle":1395,"status":256,"phases":1396,"primaryCompletion":1397,"completion":1398,"start":1399,"enrollment":261,"conditions":1400,"interventions":1401},"NCT03616405","Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection",[93],"2019-11-30","2020-04-30","2019-04-01",[16],[1371],{"trials":1403,"activeCount":102},[],{"intervention":1106,"totalTrials":762,"cells":1405},{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1410,"PHASE3":1412,"PHASE4":1414,"NA":1430},{"trials":1407,"activeCount":102},[],{"trials":1409,"activeCount":102},[],{"trials":1411,"activeCount":102},[],{"trials":1413,"activeCount":102},[],{"trials":1415,"activeCount":102},[1416,1426],{"nctId":1417,"briefTitle":1418,"status":225,"phases":1419,"primaryCompletion":1420,"completion":1420,"start":1421,"enrollment":1422,"conditions":1423,"interventions":1424},"NCT03658746","Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection",[93],"2019-12-31","2019-01-01",420,[16],[1106,1425,1107],"one proton pump inhibitor, colloidal bismuth pectin",{"nctId":1096,"briefTitle":1097,"status":256,"phases":1427,"primaryCompletion":1099,"completion":1100,"start":1101,"enrollment":1102,"conditions":1428,"interventions":1429},[93],[16,1104],[1106,1107,1108,1019,1109],{"trials":1431,"activeCount":102},[],{"intervention":1107,"totalTrials":762,"cells":1433},{"EARLY_PHASE1":1434,"PHASE1":1436,"PHASE2":1438,"PHASE3":1440,"PHASE4":1442,"NA":1452},{"trials":1435,"activeCount":102},[],{"trials":1437,"activeCount":102},[],{"trials":1439,"activeCount":102},[],{"trials":1441,"activeCount":102},[],{"trials":1443,"activeCount":102},[1444,1448],{"nctId":1417,"briefTitle":1418,"status":225,"phases":1445,"primaryCompletion":1420,"completion":1420,"start":1421,"enrollment":1422,"conditions":1446,"interventions":1447},[93],[16],[1106,1425,1107],{"nctId":1096,"briefTitle":1097,"status":256,"phases":1449,"primaryCompletion":1099,"completion":1100,"start":1101,"enrollment":1102,"conditions":1450,"interventions":1451},[93],[16,1104],[1106,1107,1108,1019,1109],{"trials":1453,"activeCount":102},[],{"intervention":319,"totalTrials":762,"cells":1455},{"EARLY_PHASE1":1456,"PHASE1":1458,"PHASE2":1460,"PHASE3":1462,"PHASE4":1468,"NA":1474},{"trials":1457,"activeCount":102},[],{"trials":1459,"activeCount":102},[],{"trials":1461,"activeCount":102},[],{"trials":1463,"activeCount":102},[1464],{"nctId":311,"briefTitle":312,"status":225,"phases":1465,"primaryCompletion":314,"completion":314,"start":315,"enrollment":316,"conditions":1466,"interventions":1467},[92],[18],[319,72],{"trials":1469,"activeCount":102},[1470],{"nctId":376,"briefTitle":377,"status":225,"phases":1471,"primaryCompletion":379,"completion":380,"start":381,"enrollment":382,"conditions":1472,"interventions":1473},[93],[18],[319,72],{"trials":1475,"activeCount":102},[],{"intervention":1477,"totalTrials":762,"cells":1478},"1.2% Lugol's solution",{"EARLY_PHASE1":1479,"PHASE1":1481,"PHASE2":1483,"PHASE3":1500,"PHASE4":1502,"NA":1514},{"trials":1480,"activeCount":102},[],{"trials":1482,"activeCount":102},[],{"trials":1484,"activeCount":102},[1485],{"nctId":1486,"briefTitle":1487,"status":225,"phases":1488,"primaryCompletion":1489,"completion":1490,"start":1491,"enrollment":166,"conditions":1492,"interventions":1495},"NCT03180944","Lower Lugol's Solution Concentration on Reducing the Adverse Symptoms of Chromoendoscopy With Iodine Staining",[91],"2018-11-30","2018-12-30","2017-09-01",[1493,1494],"Mucosal Irritation","Image Quality",[1477,1496,1497,1498,1499],"1.0% Lugol's solution","0.8% Lugol's solution","0.6% Lugol's solution","0.4% Lugol's solution",{"trials":1501,"activeCount":102},[],{"trials":1503,"activeCount":102},[1504],{"nctId":1505,"briefTitle":1506,"status":256,"phases":1507,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":900,"conditions":1510,"interventions":1513},"NCT03180970","Different Lugol's Solution Concentration for Image Quality of Esophageal Lesions in Chromoendoscopy With Iodine Staining",[93],"2017-12","2017-06",[1511,1512],"Image Quality of Early Esophageal Squamous Neoplasia","Endoscopists'Subjective Assessments",[1477,1496,1497,1498,1499],{"trials":1515,"activeCount":102},[],{"intervention":1496,"totalTrials":762,"cells":1517},{"EARLY_PHASE1":1518,"PHASE1":1520,"PHASE2":1522,"PHASE3":1528,"PHASE4":1530,"NA":1536},{"trials":1519,"activeCount":102},[],{"trials":1521,"activeCount":102},[],{"trials":1523,"activeCount":102},[1524],{"nctId":1486,"briefTitle":1487,"status":225,"phases":1525,"primaryCompletion":1489,"completion":1490,"start":1491,"enrollment":166,"conditions":1526,"interventions":1527},[91],[1493,1494],[1477,1496,1497,1498,1499],{"trials":1529,"activeCount":102},[],{"trials":1531,"activeCount":102},[1532],{"nctId":1505,"briefTitle":1506,"status":256,"phases":1533,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":900,"conditions":1534,"interventions":1535},[93],[1511,1512],[1477,1496,1497,1498,1499],{"trials":1537,"activeCount":102},[],{"intervention":1497,"totalTrials":762,"cells":1539},{"EARLY_PHASE1":1540,"PHASE1":1542,"PHASE2":1544,"PHASE3":1550,"PHASE4":1552,"NA":1558},{"trials":1541,"activeCount":102},[],{"trials":1543,"activeCount":102},[],{"trials":1545,"activeCount":102},[1546],{"nctId":1486,"briefTitle":1487,"status":225,"phases":1547,"primaryCompletion":1489,"completion":1490,"start":1491,"enrollment":166,"conditions":1548,"interventions":1549},[91],[1493,1494],[1477,1496,1497,1498,1499],{"trials":1551,"activeCount":102},[],{"trials":1553,"activeCount":102},[1554],{"nctId":1505,"briefTitle":1506,"status":256,"phases":1555,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":900,"conditions":1556,"interventions":1557},[93],[1511,1512],[1477,1496,1497,1498,1499],{"trials":1559,"activeCount":102},[],{"intervention":1498,"totalTrials":762,"cells":1561},{"EARLY_PHASE1":1562,"PHASE1":1564,"PHASE2":1566,"PHASE3":1572,"PHASE4":1574,"NA":1580},{"trials":1563,"activeCount":102},[],{"trials":1565,"activeCount":102},[],{"trials":1567,"activeCount":102},[1568],{"nctId":1486,"briefTitle":1487,"status":225,"phases":1569,"primaryCompletion":1489,"completion":1490,"start":1491,"enrollment":166,"conditions":1570,"interventions":1571},[91],[1493,1494],[1477,1496,1497,1498,1499],{"trials":1573,"activeCount":102},[],{"trials":1575,"activeCount":102},[1576],{"nctId":1505,"briefTitle":1506,"status":256,"phases":1577,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":900,"conditions":1578,"interventions":1579},[93],[1511,1512],[1477,1496,1497,1498,1499],{"trials":1581,"activeCount":102},[],{"intervention":1499,"totalTrials":762,"cells":1583},{"EARLY_PHASE1":1584,"PHASE1":1586,"PHASE2":1588,"PHASE3":1594,"PHASE4":1596,"NA":1602},{"trials":1585,"activeCount":102},[],{"trials":1587,"activeCount":102},[],{"trials":1589,"activeCount":102},[1590],{"nctId":1486,"briefTitle":1487,"status":225,"phases":1591,"primaryCompletion":1489,"completion":1490,"start":1491,"enrollment":166,"conditions":1592,"interventions":1593},[91],[1493,1494],[1477,1496,1497,1498,1499],{"trials":1595,"activeCount":102},[],{"trials":1597,"activeCount":102},[1598],{"nctId":1505,"briefTitle":1506,"status":256,"phases":1599,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":900,"conditions":1600,"interventions":1601},[93],[1511,1512],[1477,1496,1497,1498,1499],{"trials":1603,"activeCount":102},[],{"intervention":1605,"totalTrials":762,"cells":1606},"Tacrolimus",{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1611,"PHASE3":1613,"PHASE4":1615,"NA":1639},{"trials":1608,"activeCount":102},[],{"trials":1610,"activeCount":102},[],{"trials":1612,"activeCount":102},[],{"trials":1614,"activeCount":102},[],{"trials":1616,"activeCount":102},[1617,1627],{"nctId":1618,"briefTitle":1619,"status":225,"phases":1620,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":1624,"interventions":1626},"NCT03347357","Pharmacokinetics of Tacrolimus in Children",[93],"2017-09-30","2012-01-01",28,[1625],"Nephrotic Syndrome",[1605],{"nctId":1628,"briefTitle":1629,"status":225,"phases":1630,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":1634,"interventions":1636},"NCT03222687","Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis",[93],"2017-05-31","2015-09-01",25,[1635],"Henoch-Schönlein Purpura Nephritis",[1637,1638],"tacrolimus","prednisone",{"trials":1640,"activeCount":102},[],{"intervention":1638,"totalTrials":762,"cells":1642},{"EARLY_PHASE1":1643,"PHASE1":1645,"PHASE2":1647,"PHASE3":1649,"PHASE4":1651,"NA":1661},{"trials":1644,"activeCount":102},[],{"trials":1646,"activeCount":102},[],{"trials":1648,"activeCount":102},[],{"trials":1650,"activeCount":102},[],{"trials":1652,"activeCount":102},[1653,1657],{"nctId":1628,"briefTitle":1629,"status":225,"phases":1654,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":1655,"interventions":1656},[93],[1635],[1637,1638],{"nctId":386,"briefTitle":387,"status":225,"phases":1658,"primaryCompletion":271,"completion":389,"start":390,"enrollment":391,"conditions":1659,"interventions":1660},[93],[295],[394,72],{"trials":1662,"activeCount":102},[],{"intervention":1017,"totalTrials":762,"cells":1664},{"EARLY_PHASE1":1665,"PHASE1":1667,"PHASE2":1669,"PHASE3":1671,"PHASE4":1673,"NA":1683},{"trials":1666,"activeCount":102},[],{"trials":1668,"activeCount":102},[],{"trials":1670,"activeCount":102},[],{"trials":1672,"activeCount":102},[],{"trials":1674,"activeCount":102},[1675,1679],{"nctId":1006,"briefTitle":1007,"status":225,"phases":1676,"primaryCompletion":1009,"completion":1010,"start":1011,"enrollment":1012,"conditions":1677,"interventions":1678},[93],[16],[1015,1016,1017,971,1018,1019,1020],{"nctId":1022,"briefTitle":1023,"status":256,"phases":1680,"primaryCompletion":1025,"completion":1026,"start":1027,"enrollment":1012,"conditions":1681,"interventions":1682},[93],[16],[1015,1016,1017,971,1018,1019,1020],{"trials":1684,"activeCount":102},[],{"intervention":1020,"totalTrials":762,"cells":1686},{"EARLY_PHASE1":1687,"PHASE1":1689,"PHASE2":1691,"PHASE3":1693,"PHASE4":1695,"NA":1705},{"trials":1688,"activeCount":102},[],{"trials":1690,"activeCount":102},[],{"trials":1692,"activeCount":102},[],{"trials":1694,"activeCount":102},[],{"trials":1696,"activeCount":102},[1697,1701],{"nctId":1006,"briefTitle":1007,"status":225,"phases":1698,"primaryCompletion":1009,"completion":1010,"start":1011,"enrollment":1012,"conditions":1699,"interventions":1700},[93],[16],[1015,1016,1017,971,1018,1019,1020],{"nctId":1022,"briefTitle":1023,"status":256,"phases":1702,"primaryCompletion":1025,"completion":1026,"start":1027,"enrollment":1012,"conditions":1703,"interventions":1704},[93],[16],[1015,1016,1017,971,1018,1019,1020],{"trials":1706,"activeCount":102},[],{"intervention":1708,"totalTrials":98,"cells":1709},"Standard Bowel Prep",{"EARLY_PHASE1":1710,"PHASE1":1712,"PHASE2":1714,"PHASE3":1716,"PHASE4":1718,"NA":1729},{"trials":1711,"activeCount":102},[],{"trials":1713,"activeCount":102},[],{"trials":1715,"activeCount":102},[],{"trials":1717,"activeCount":102},[],{"trials":1719,"activeCount":102},[1720],{"nctId":1721,"briefTitle":1722,"status":225,"phases":1723,"primaryCompletion":1355,"completion":1355,"start":269,"enrollment":1724,"conditions":1725,"interventions":1727},"NCT02415569","Tailored Bowel Preparation According to Bristol Stool Form Scale",[93],700,[1726],"Bowel Cleansing Quality",[1708,1728,1708],"2L PEG-ELP and 10mg bisacodyl",{"trials":1730,"activeCount":102},[],{"intervention":1728,"totalTrials":98,"cells":1732},{"EARLY_PHASE1":1733,"PHASE1":1735,"PHASE2":1737,"PHASE3":1739,"PHASE4":1741,"NA":1747},{"trials":1734,"activeCount":102},[],{"trials":1736,"activeCount":102},[],{"trials":1738,"activeCount":102},[],{"trials":1740,"activeCount":102},[],{"trials":1742,"activeCount":102},[1743],{"nctId":1721,"briefTitle":1722,"status":225,"phases":1744,"primaryCompletion":1355,"completion":1355,"start":269,"enrollment":1724,"conditions":1745,"interventions":1746},[93],[1726],[1708,1728,1708],{"trials":1748,"activeCount":102},[],{"intervention":1750,"totalTrials":98,"cells":1751},"Clostridium Butyricum",{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1758,"PHASE4":1760,"NA":1770},{"trials":1753,"activeCount":102},[],{"trials":1755,"activeCount":102},[],{"trials":1757,"activeCount":102},[],{"trials":1759,"activeCount":102},[],{"trials":1761,"activeCount":102},[1762],{"nctId":1763,"briefTitle":1764,"status":256,"phases":1765,"primaryCompletion":1766,"completion":1766,"start":1767,"enrollment":118,"conditions":1768,"interventions":1769},"NCT02614963","Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome",[93],"2016-07","2015-12",[1764],[1750],{"trials":1771,"activeCount":102},[],{"intervention":1773,"totalTrials":98,"cells":1774},"10-day Tegoprazan bismuth-containing quadruple therapy",{"EARLY_PHASE1":1775,"PHASE1":1777,"PHASE2":1779,"PHASE3":1781,"PHASE4":1783,"NA":1795},{"trials":1776,"activeCount":102},[],{"trials":1778,"activeCount":102},[],{"trials":1780,"activeCount":102},[],{"trials":1782,"activeCount":102},[],{"trials":1784,"activeCount":102},[1785],{"nctId":1786,"briefTitle":1787,"status":256,"phases":1788,"primaryCompletion":1789,"completion":1790,"start":1791,"enrollment":1792,"conditions":1793,"interventions":1794},"NCT05586113","The Efficacy of 10-day or 14-day Course of Bismuth-containing Quadruple Therapy:A Randomized Clinical Trial",[93],"2023-10-31","2023-12-31","2023-02-06",398,[16],[1773],{"trials":1796,"activeCount":102},[],{"intervention":1798,"totalTrials":98,"cells":1799},"Tetracycline 500mg tid",{"EARLY_PHASE1":1800,"PHASE1":1802,"PHASE2":1804,"PHASE3":1806,"PHASE4":1808,"NA":1820},{"trials":1801,"activeCount":102},[],{"trials":1803,"activeCount":102},[],{"trials":1805,"activeCount":102},[],{"trials":1807,"activeCount":102},[],{"trials":1809,"activeCount":102},[1810],{"nctId":1811,"briefTitle":1812,"status":256,"phases":1813,"primaryCompletion":1814,"completion":1814,"start":1815,"enrollment":1816,"conditions":1817,"interventions":1818},"NCT05802888","Bismuth Quadruple Therapy in Helicobacter Pylori Rescue Therapy of Different Tetracycline Doses and Frequencies.",[93],"2024-06-15","2023-03-12",260,[16],[1798,1819],"Tetracycline 500mg qid",{"trials":1821,"activeCount":102},[],{"intervention":1819,"totalTrials":98,"cells":1823},{"EARLY_PHASE1":1824,"PHASE1":1826,"PHASE2":1828,"PHASE3":1830,"PHASE4":1832,"NA":1838},{"trials":1825,"activeCount":102},[],{"trials":1827,"activeCount":102},[],{"trials":1829,"activeCount":102},[],{"trials":1831,"activeCount":102},[],{"trials":1833,"activeCount":102},[1834],{"nctId":1811,"briefTitle":1812,"status":256,"phases":1835,"primaryCompletion":1814,"completion":1814,"start":1815,"enrollment":1816,"conditions":1836,"interventions":1837},[93],[16],[1798,1819],{"trials":1839,"activeCount":102},[],{"intervention":1841,"totalTrials":98,"cells":1842},"S-1",{"EARLY_PHASE1":1843,"PHASE1":1845,"PHASE2":1847,"PHASE3":1849,"PHASE4":1851,"NA":1865},{"trials":1844,"activeCount":102},[],{"trials":1846,"activeCount":102},[],{"trials":1848,"activeCount":102},[],{"trials":1850,"activeCount":102},[],{"trials":1852,"activeCount":102},[1853],{"nctId":1854,"briefTitle":1855,"status":256,"phases":1856,"primaryCompletion":241,"completion":1857,"start":1858,"enrollment":1859,"conditions":1860,"interventions":1863},"NCT01849380","Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer",[93],"2018-06","2013-06",240,[1861,1862],"Breast Neoplasms","Neoadjuvant Therapy",[1841,1864],"5-FU",{"trials":1866,"activeCount":102},[],{"intervention":1864,"totalTrials":98,"cells":1868},{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1873,"PHASE3":1875,"PHASE4":1877,"NA":1883},{"trials":1870,"activeCount":102},[],{"trials":1872,"activeCount":102},[],{"trials":1874,"activeCount":102},[],{"trials":1876,"activeCount":102},[],{"trials":1878,"activeCount":102},[1879],{"nctId":1854,"briefTitle":1855,"status":256,"phases":1880,"primaryCompletion":241,"completion":1857,"start":1858,"enrollment":1859,"conditions":1881,"interventions":1882},[93],[1861,1862],[1841,1864],{"trials":1884,"activeCount":102},[],{"intervention":1365,"totalTrials":98,"cells":1886},{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1891,"PHASE3":1893,"PHASE4":1895,"NA":1901},{"trials":1888,"activeCount":102},[],{"trials":1890,"activeCount":102},[],{"trials":1892,"activeCount":102},[],{"trials":1894,"activeCount":102},[],{"trials":1896,"activeCount":102},[1897],{"nctId":1360,"briefTitle":1361,"status":256,"phases":1898,"primaryCompletion":1354,"completion":1354,"start":1355,"enrollment":166,"conditions":1899,"interventions":1900},[93],[168],[1338,1365,1366,1367],{"trials":1902,"activeCount":102},[],{"intervention":1366,"totalTrials":98,"cells":1904},{"EARLY_PHASE1":1905,"PHASE1":1907,"PHASE2":1909,"PHASE3":1911,"PHASE4":1913,"NA":1919},{"trials":1906,"activeCount":102},[],{"trials":1908,"activeCount":102},[],{"trials":1910,"activeCount":102},[],{"trials":1912,"activeCount":102},[],{"trials":1914,"activeCount":102},[1915],{"nctId":1360,"briefTitle":1361,"status":256,"phases":1916,"primaryCompletion":1354,"completion":1354,"start":1355,"enrollment":166,"conditions":1917,"interventions":1918},[93],[168],[1338,1365,1366,1367],{"trials":1920,"activeCount":102},[],{"intervention":1367,"totalTrials":98,"cells":1922},{"EARLY_PHASE1":1923,"PHASE1":1925,"PHASE2":1927,"PHASE3":1929,"PHASE4":1931,"NA":1937},{"trials":1924,"activeCount":102},[],{"trials":1926,"activeCount":102},[],{"trials":1928,"activeCount":102},[],{"trials":1930,"activeCount":102},[],{"trials":1932,"activeCount":102},[1933],{"nctId":1360,"briefTitle":1361,"status":256,"phases":1934,"primaryCompletion":1354,"completion":1354,"start":1355,"enrollment":166,"conditions":1935,"interventions":1936},[93],[168],[1338,1365,1366,1367],{"trials":1938,"activeCount":102},[],{"intervention":1940,"totalTrials":98,"cells":1941},"PEG-rhG-CSF",{"EARLY_PHASE1":1942,"PHASE1":1944,"PHASE2":1946,"PHASE3":1948,"PHASE4":1950,"NA":1963},{"trials":1943,"activeCount":102},[],{"trials":1945,"activeCount":102},[],{"trials":1947,"activeCount":102},[],{"trials":1949,"activeCount":102},[],{"trials":1951,"activeCount":102},[1952],{"nctId":1953,"briefTitle":1954,"status":1955,"phases":1956,"primaryCompletion":1187,"completion":1187,"start":1957,"enrollment":1958,"conditions":1959,"interventions":1962},"NCT03858166","Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer","TERMINATED",[93],"2017-12-01",68,[1960,1961,725],"Adjuvant Chemotherapy","Ovarian Neoplasms",[1940],{"trials":1964,"activeCount":102},[],{"intervention":1392,"totalTrials":98,"cells":1966},{"EARLY_PHASE1":1967,"PHASE1":1969,"PHASE2":1971,"PHASE3":1973,"PHASE4":1975,"NA":1981},{"trials":1968,"activeCount":102},[],{"trials":1970,"activeCount":102},[],{"trials":1972,"activeCount":102},[],{"trials":1974,"activeCount":102},[],{"trials":1976,"activeCount":102},[1977],{"nctId":1384,"briefTitle":1385,"status":256,"phases":1978,"primaryCompletion":1159,"completion":1387,"start":1388,"enrollment":1389,"conditions":1979,"interventions":1980},[93],[16],[1392,1371],{"trials":1982,"activeCount":102},[],{"intervention":1984,"totalTrials":98,"cells":1985},"Tobramycin",{"EARLY_PHASE1":1986,"PHASE1":1988,"PHASE2":1990,"PHASE3":1992,"PHASE4":1994,"NA":2005},{"trials":1987,"activeCount":102},[],{"trials":1989,"activeCount":102},[],{"trials":1991,"activeCount":102},[],{"trials":1993,"activeCount":102},[],{"trials":1995,"activeCount":102},[1996],{"nctId":1997,"briefTitle":1998,"status":256,"phases":1999,"primaryCompletion":240,"completion":240,"start":2000,"enrollment":1389,"conditions":2001,"interventions":2003},"NCT01677403","A Study to Access Safety and Efficacy of Nebulized Tobramycin in Patients With Bronchiectasis",[93],"2012-08",[2002],"Bronchiectasis",[1984,2004],"Saline",{"trials":2006,"activeCount":102},[],{"intervention":2004,"totalTrials":98,"cells":2008},{"EARLY_PHASE1":2009,"PHASE1":2011,"PHASE2":2013,"PHASE3":2015,"PHASE4":2017,"NA":2023},{"trials":2010,"activeCount":102},[],{"trials":2012,"activeCount":102},[],{"trials":2014,"activeCount":102},[],{"trials":2016,"activeCount":102},[],{"trials":2018,"activeCount":102},[2019],{"nctId":1997,"briefTitle":1998,"status":256,"phases":2020,"primaryCompletion":240,"completion":240,"start":2000,"enrollment":1389,"conditions":2021,"interventions":2022},[93],[2002],[1984,2004],{"trials":2024,"activeCount":102},[],{"intervention":2026,"totalTrials":98,"cells":2027},"50-200mg propofol",{"EARLY_PHASE1":2028,"PHASE1":2030,"PHASE2":2032,"PHASE3":2034,"PHASE4":2036,"NA":2049},{"trials":2029,"activeCount":102},[],{"trials":2031,"activeCount":102},[],{"trials":2033,"activeCount":102},[],{"trials":2035,"activeCount":102},[],{"trials":2037,"activeCount":102},[2038],{"nctId":2039,"briefTitle":2040,"status":256,"phases":2041,"primaryCompletion":2042,"completion":2043,"start":1421,"enrollment":879,"conditions":2044,"interventions":2046},"NCT03803449","Patient Satisfaction and Safety With Propofol Based Sedation With or Without Fentanyl for Gastrointestinal Endoscopy",[93],"2019-07-30","2019-10-30",[2045],"Patient Satisfaction",[2026,2047,2048],"50ug fentanyl","1 mg midazolam",{"trials":2050,"activeCount":102},[],{"intervention":2047,"totalTrials":98,"cells":2052},{"EARLY_PHASE1":2053,"PHASE1":2055,"PHASE2":2057,"PHASE3":2059,"PHASE4":2061,"NA":2067},{"trials":2054,"activeCount":102},[],{"trials":2056,"activeCount":102},[],{"trials":2058,"activeCount":102},[],{"trials":2060,"activeCount":102},[],{"trials":2062,"activeCount":102},[2063],{"nctId":2039,"briefTitle":2040,"status":256,"phases":2064,"primaryCompletion":2042,"completion":2043,"start":1421,"enrollment":879,"conditions":2065,"interventions":2066},[93],[2045],[2026,2047,2048],{"trials":2068,"activeCount":102},[],{"intervention":2048,"totalTrials":98,"cells":2070},{"EARLY_PHASE1":2071,"PHASE1":2073,"PHASE2":2075,"PHASE3":2077,"PHASE4":2079,"NA":2085},{"trials":2072,"activeCount":102},[],{"trials":2074,"activeCount":102},[],{"trials":2076,"activeCount":102},[],{"trials":2078,"activeCount":102},[],{"trials":2080,"activeCount":102},[2081],{"nctId":2039,"briefTitle":2040,"status":256,"phases":2082,"primaryCompletion":2042,"completion":2043,"start":1421,"enrollment":879,"conditions":2083,"interventions":2084},[93],[2045],[2026,2047,2048],{"trials":2086,"activeCount":102},[],{"intervention":2088,"totalTrials":98,"cells":2089},"EuBone ®",{"EARLY_PHASE1":2090,"PHASE1":2092,"PHASE2":2094,"PHASE3":2096,"PHASE4":2098,"NA":2109},{"trials":2091,"activeCount":102},[],{"trials":2093,"activeCount":102},[],{"trials":2095,"activeCount":102},[],{"trials":2097,"activeCount":102},[],{"trials":2099,"activeCount":102},[2100],{"nctId":2101,"briefTitle":2102,"status":256,"phases":2103,"primaryCompletion":2104,"completion":1790,"start":2105,"enrollment":304,"conditions":2106,"interventions":2108},"NCT05402852","Effectiveness and Safety of EuBone® Capsules for Bone Health in Postmenopausal Women",[93],"2022-10-31","2022-06-01",[2107],"Osteoporosis, Postmenopausal",[2088],{"trials":2110,"activeCount":102},[],{"intervention":1425,"totalTrials":98,"cells":2112},{"EARLY_PHASE1":2113,"PHASE1":2115,"PHASE2":2117,"PHASE3":2119,"PHASE4":2121,"NA":2127},{"trials":2114,"activeCount":102},[],{"trials":2116,"activeCount":102},[],{"trials":2118,"activeCount":102},[],{"trials":2120,"activeCount":102},[],{"trials":2122,"activeCount":102},[2123],{"nctId":1417,"briefTitle":1418,"status":225,"phases":2124,"primaryCompletion":1420,"completion":1420,"start":1421,"enrollment":1422,"conditions":2125,"interventions":2126},[93],[16],[1106,1425,1107],{"trials":2128,"activeCount":102},[],{"intervention":2130,"totalTrials":98,"cells":2131},"Lansoprazole, Amoxicillin",{"EARLY_PHASE1":2132,"PHASE1":2134,"PHASE2":2136,"PHASE3":2138,"PHASE4":2140,"NA":2153},{"trials":2133,"activeCount":102},[],{"trials":2135,"activeCount":102},[],{"trials":2137,"activeCount":102},[],{"trials":2139,"activeCount":102},[],{"trials":2141,"activeCount":102},[2142],{"nctId":2143,"briefTitle":2144,"status":256,"phases":2145,"primaryCompletion":2146,"completion":2147,"start":2148,"enrollment":2149,"conditions":2150,"interventions":2151},"NCT04101708","A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients",[93],"2021-09-20","2022-09-20","2019-09-20",100,[27],[2130,2152],"Lansoprazole, Amoxicillin,Clarithromycin and Bismuth subcitrate",{"trials":2154,"activeCount":102},[],{"intervention":2152,"totalTrials":98,"cells":2156},{"EARLY_PHASE1":2157,"PHASE1":2159,"PHASE2":2161,"PHASE3":2163,"PHASE4":2165,"NA":2171},{"trials":2158,"activeCount":102},[],{"trials":2160,"activeCount":102},[],{"trials":2162,"activeCount":102},[],{"trials":2164,"activeCount":102},[],{"trials":2166,"activeCount":102},[2167],{"nctId":2143,"briefTitle":2144,"status":256,"phases":2168,"primaryCompletion":2146,"completion":2147,"start":2148,"enrollment":2149,"conditions":2169,"interventions":2170},[93],[27],[2130,2152],{"trials":2172,"activeCount":102},[],{"intervention":2174,"totalTrials":98,"cells":2175},"standard preparation",{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2180,"PHASE3":2182,"PHASE4":2184,"NA":2196},{"trials":2177,"activeCount":102},[],{"trials":2179,"activeCount":102},[],{"trials":2181,"activeCount":102},[],{"trials":2183,"activeCount":102},[],{"trials":2185,"activeCount":102},[2186],{"nctId":2187,"briefTitle":2188,"status":256,"phases":2189,"primaryCompletion":2190,"completion":2190,"start":2191,"enrollment":118,"conditions":2192,"interventions":2193},"NCT02761317","Optimal Bowel Preparation Regimen in Patients With Colorectal Surgery",[93],"2016-11","2016-05",[36],[2174,2194,2195],"low-volume preparation","high-volume preparation",{"trials":2197,"activeCount":102},[],{"intervention":2194,"totalTrials":98,"cells":2199},{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2204,"PHASE3":2206,"PHASE4":2208,"NA":2214},{"trials":2201,"activeCount":102},[],{"trials":2203,"activeCount":102},[],{"trials":2205,"activeCount":102},[],{"trials":2207,"activeCount":102},[],{"trials":2209,"activeCount":102},[2210],{"nctId":2187,"briefTitle":2188,"status":256,"phases":2211,"primaryCompletion":2190,"completion":2190,"start":2191,"enrollment":118,"conditions":2212,"interventions":2213},[93],[36],[2174,2194,2195],{"trials":2215,"activeCount":102},[],{"intervention":2195,"totalTrials":98,"cells":2217},{"EARLY_PHASE1":2218,"PHASE1":2220,"PHASE2":2222,"PHASE3":2224,"PHASE4":2226,"NA":2232},{"trials":2219,"activeCount":102},[],{"trials":2221,"activeCount":102},[],{"trials":2223,"activeCount":102},[],{"trials":2225,"activeCount":102},[],{"trials":2227,"activeCount":102},[2228],{"nctId":2187,"briefTitle":2188,"status":256,"phases":2229,"primaryCompletion":2190,"completion":2190,"start":2191,"enrollment":118,"conditions":2230,"interventions":2231},[93],[36],[2174,2194,2195],{"trials":2233,"activeCount":102},[],{"intervention":2235,"totalTrials":98,"cells":2236},"Mercaptopurine",{"EARLY_PHASE1":2237,"PHASE1":2239,"PHASE2":2241,"PHASE3":2243,"PHASE4":2245,"NA":2255},{"trials":2238,"activeCount":102},[],{"trials":2240,"activeCount":102},[],{"trials":2242,"activeCount":102},[],{"trials":2244,"activeCount":102},[],{"trials":2246,"activeCount":102},[2247],{"nctId":2248,"briefTitle":2249,"status":256,"phases":2250,"primaryCompletion":2251,"completion":2251,"start":269,"enrollment":879,"conditions":2252,"interventions":2254},"NCT03920813","Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance Therapy",[93],"2021-12",[2253],"Acute Lymphoblastic Leukemia",[2235],{"trials":2256,"activeCount":102},[],{"intervention":2258,"totalTrials":98,"cells":2259},"2 mg Prucalopride plus 2 L Polyethylene Glycol regimen",{"EARLY_PHASE1":2260,"PHASE1":2262,"PHASE2":2264,"PHASE3":2266,"PHASE4":2268,"NA":2281},{"trials":2261,"activeCount":102},[],{"trials":2263,"activeCount":102},[],{"trials":2265,"activeCount":102},[],{"trials":2267,"activeCount":102},[],{"trials":2269,"activeCount":102},[2270],{"nctId":2271,"briefTitle":2272,"status":256,"phases":2273,"primaryCompletion":2274,"completion":2274,"start":2275,"enrollment":2276,"conditions":2277,"interventions":2279},"NCT02781493","Efficacy of Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopy",[93],"2017-03","2016-06",600,[2278],"Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopyp",[2258,2280],"2 mg Placebo plus 2 L Polyethylene Glycol regimen",{"trials":2282,"activeCount":102},[],{"intervention":2280,"totalTrials":98,"cells":2284},{"EARLY_PHASE1":2285,"PHASE1":2287,"PHASE2":2289,"PHASE3":2291,"PHASE4":2293,"NA":2299},{"trials":2286,"activeCount":102},[],{"trials":2288,"activeCount":102},[],{"trials":2290,"activeCount":102},[],{"trials":2292,"activeCount":102},[],{"trials":2294,"activeCount":102},[2295],{"nctId":2271,"briefTitle":2272,"status":256,"phases":2296,"primaryCompletion":2274,"completion":2274,"start":2275,"enrollment":2276,"conditions":2297,"interventions":2298},[93],[2278],[2258,2280],{"trials":2300,"activeCount":102},[],{"intervention":2302,"totalTrials":98,"cells":2303},"Clarithromycin susceptibility dependant strategy",{"EARLY_PHASE1":2304,"PHASE1":2306,"PHASE2":2308,"PHASE3":2310,"PHASE4":2312,"NA":2328},{"trials":2305,"activeCount":102},[],{"trials":2307,"activeCount":102},[],{"trials":2309,"activeCount":102},[],{"trials":2311,"activeCount":102},[],{"trials":2313,"activeCount":102},[2314],{"nctId":2315,"briefTitle":2316,"status":256,"phases":2317,"primaryCompletion":2318,"completion":2318,"start":2319,"enrollment":2320,"conditions":2321,"interventions":2322},"NCT02988089","Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment",[93],"2017-09","2017-04-20",480,[16,1104],[2302,2323,2324,2325,2326,2327],"2 susceptible antibiotics","proton pump inhibitor (PPI) and Colloidal Bismuth Pectin","amoxicillin and clarithromycin or amoxicillin and furazolidone","amoxicillin and furazolidone or amoxicillin and tetracycline","amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin",{"trials":2329,"activeCount":102},[],{"intervention":2323,"totalTrials":98,"cells":2331},{"EARLY_PHASE1":2332,"PHASE1":2334,"PHASE2":2336,"PHASE3":2338,"PHASE4":2340,"NA":2346},{"trials":2333,"activeCount":102},[],{"trials":2335,"activeCount":102},[],{"trials":2337,"activeCount":102},[],{"trials":2339,"activeCount":102},[],{"trials":2341,"activeCount":102},[2342],{"nctId":2315,"briefTitle":2316,"status":256,"phases":2343,"primaryCompletion":2318,"completion":2318,"start":2319,"enrollment":2320,"conditions":2344,"interventions":2345},[93],[16,1104],[2302,2323,2324,2325,2326,2327],{"trials":2347,"activeCount":102},[],{"intervention":2324,"totalTrials":98,"cells":2349},{"EARLY_PHASE1":2350,"PHASE1":2352,"PHASE2":2354,"PHASE3":2356,"PHASE4":2358,"NA":2364},{"trials":2351,"activeCount":102},[],{"trials":2353,"activeCount":102},[],{"trials":2355,"activeCount":102},[],{"trials":2357,"activeCount":102},[],{"trials":2359,"activeCount":102},[2360],{"nctId":2315,"briefTitle":2316,"status":256,"phases":2361,"primaryCompletion":2318,"completion":2318,"start":2319,"enrollment":2320,"conditions":2362,"interventions":2363},[93],[16,1104],[2302,2323,2324,2325,2326,2327],{"trials":2365,"activeCount":102},[],{"intervention":2325,"totalTrials":98,"cells":2367},{"EARLY_PHASE1":2368,"PHASE1":2370,"PHASE2":2372,"PHASE3":2374,"PHASE4":2376,"NA":2382},{"trials":2369,"activeCount":102},[],{"trials":2371,"activeCount":102},[],{"trials":2373,"activeCount":102},[],{"trials":2375,"activeCount":102},[],{"trials":2377,"activeCount":102},[2378],{"nctId":2315,"briefTitle":2316,"status":256,"phases":2379,"primaryCompletion":2318,"completion":2318,"start":2319,"enrollment":2320,"conditions":2380,"interventions":2381},[93],[16,1104],[2302,2323,2324,2325,2326,2327],{"trials":2383,"activeCount":102},[],{"intervention":2326,"totalTrials":98,"cells":2385},{"EARLY_PHASE1":2386,"PHASE1":2388,"PHASE2":2390,"PHASE3":2392,"PHASE4":2394,"NA":2400},{"trials":2387,"activeCount":102},[],{"trials":2389,"activeCount":102},[],{"trials":2391,"activeCount":102},[],{"trials":2393,"activeCount":102},[],{"trials":2395,"activeCount":102},[2396],{"nctId":2315,"briefTitle":2316,"status":256,"phases":2397,"primaryCompletion":2318,"completion":2318,"start":2319,"enrollment":2320,"conditions":2398,"interventions":2399},[93],[16,1104],[2302,2323,2324,2325,2326,2327],{"trials":2401,"activeCount":102},[],{"intervention":2327,"totalTrials":98,"cells":2403},{"EARLY_PHASE1":2404,"PHASE1":2406,"PHASE2":2408,"PHASE3":2410,"PHASE4":2412,"NA":2418},{"trials":2405,"activeCount":102},[],{"trials":2407,"activeCount":102},[],{"trials":2409,"activeCount":102},[],{"trials":2411,"activeCount":102},[],{"trials":2413,"activeCount":102},[2414],{"nctId":2315,"briefTitle":2316,"status":256,"phases":2415,"primaryCompletion":2318,"completion":2318,"start":2319,"enrollment":2320,"conditions":2416,"interventions":2417},[93],[16,1104],[2302,2323,2324,2325,2326,2327],{"trials":2419,"activeCount":102},[],{"intervention":365,"totalTrials":98,"cells":2421},{"EARLY_PHASE1":2422,"PHASE1":2424,"PHASE2":2426,"PHASE3":2428,"PHASE4":2430,"NA":2436},{"trials":2423,"activeCount":102},[],{"trials":2425,"activeCount":102},[],{"trials":2427,"activeCount":102},[],{"trials":2429,"activeCount":102},[],{"trials":2431,"activeCount":102},[2432],{"nctId":357,"briefTitle":358,"status":256,"phases":2433,"primaryCompletion":360,"completion":361,"start":362,"enrollment":261,"conditions":2434,"interventions":2435},[93],[18],[365,72],{"trials":2437,"activeCount":102},[],{"intervention":1108,"totalTrials":98,"cells":2439},{"EARLY_PHASE1":2440,"PHASE1":2442,"PHASE2":2444,"PHASE3":2446,"PHASE4":2448,"NA":2454},{"trials":2441,"activeCount":102},[],{"trials":2443,"activeCount":102},[],{"trials":2445,"activeCount":102},[],{"trials":2447,"activeCount":102},[],{"trials":2449,"activeCount":102},[2450],{"nctId":1096,"briefTitle":1097,"status":256,"phases":2451,"primaryCompletion":1099,"completion":1100,"start":1101,"enrollment":1102,"conditions":2452,"interventions":2453},[93],[16,1104],[1106,1107,1108,1019,1109],{"trials":2455,"activeCount":102},[],{"intervention":1109,"totalTrials":98,"cells":2457},{"EARLY_PHASE1":2458,"PHASE1":2460,"PHASE2":2462,"PHASE3":2464,"PHASE4":2466,"NA":2472},{"trials":2459,"activeCount":102},[],{"trials":2461,"activeCount":102},[],{"trials":2463,"activeCount":102},[],{"trials":2465,"activeCount":102},[],{"trials":2467,"activeCount":102},[2468],{"nctId":1096,"briefTitle":1097,"status":256,"phases":2469,"primaryCompletion":1099,"completion":1100,"start":1101,"enrollment":1102,"conditions":2470,"interventions":2471},[93],[16,1104],[1106,1107,1108,1019,1109],{"trials":2473,"activeCount":102},[],{"intervention":2475,"totalTrials":98,"cells":2476},"Piperacillin\u002Ftazobactam",{"EARLY_PHASE1":2477,"PHASE1":2479,"PHASE2":2481,"PHASE3":2483,"PHASE4":2485,"NA":2498},{"trials":2478,"activeCount":102},[],{"trials":2480,"activeCount":102},[],{"trials":2482,"activeCount":102},[],{"trials":2484,"activeCount":102},[],{"trials":2486,"activeCount":102},[2487],{"nctId":2488,"briefTitle":2489,"status":256,"phases":2490,"primaryCompletion":2491,"completion":2492,"start":2493,"enrollment":2494,"conditions":2495,"interventions":2497},"NCT05981079","Model-based Dose Versus Empirical Dose of Piperacillin\u002FTazobactam in Preterm Neonates With Late-onset Sepsis.",[93],"2024-12-31","2025-05-31","2023-07-31",332,[2496],"Late-Onset Neonatal Sepsis",[2475],{"trials":2499,"activeCount":102},[],{"intervention":374,"totalTrials":98,"cells":2501},{"EARLY_PHASE1":2502,"PHASE1":2504,"PHASE2":2506,"PHASE3":2508,"PHASE4":2510,"NA":2516},{"trials":2503,"activeCount":102},[],{"trials":2505,"activeCount":102},[],{"trials":2507,"activeCount":102},[],{"trials":2509,"activeCount":102},[],{"trials":2511,"activeCount":102},[2512],{"nctId":367,"briefTitle":368,"status":256,"phases":2513,"primaryCompletion":370,"completion":370,"start":371,"enrollment":304,"conditions":2514,"interventions":2515},[93],[18],[374,72],{"trials":2517,"activeCount":102},[],{"intervention":2519,"totalTrials":98,"cells":2520},"Modified non-clarithromycin triple therapy",{"EARLY_PHASE1":2521,"PHASE1":2523,"PHASE2":2525,"PHASE3":2527,"PHASE4":2529,"NA":2542},{"trials":2522,"activeCount":102},[],{"trials":2524,"activeCount":102},[],{"trials":2526,"activeCount":102},[],{"trials":2528,"activeCount":102},[],{"trials":2530,"activeCount":102},[2531],{"nctId":2532,"briefTitle":2533,"status":225,"phases":2534,"primaryCompletion":2535,"completion":258,"start":2536,"enrollment":2537,"conditions":2538,"interventions":2540},"NCT02776371","Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori",[93],"2018-01","2016-09",301,[2539],"Helicobacter Pylori Eradication Rate",[2519,2541],"Sequential therapy",{"trials":2543,"activeCount":102},[],{"intervention":2541,"totalTrials":98,"cells":2545},{"EARLY_PHASE1":2546,"PHASE1":2548,"PHASE2":2550,"PHASE3":2552,"PHASE4":2554,"NA":2560},{"trials":2547,"activeCount":102},[],{"trials":2549,"activeCount":102},[],{"trials":2551,"activeCount":102},[],{"trials":2553,"activeCount":102},[],{"trials":2555,"activeCount":102},[2556],{"nctId":2532,"briefTitle":2533,"status":225,"phases":2557,"primaryCompletion":2535,"completion":258,"start":2536,"enrollment":2537,"conditions":2558,"interventions":2559},[93],[2539],[2519,2541],{"trials":2561,"activeCount":102},[],{"intervention":2563,"totalTrials":98,"cells":2564},"lower fluorescein sodium dosage 0.02ml\u002Fkg",{"EARLY_PHASE1":2565,"PHASE1":2567,"PHASE2":2569,"PHASE3":2571,"PHASE4":2573,"NA":2584},{"trials":2566,"activeCount":102},[],{"trials":2568,"activeCount":102},[],{"trials":2570,"activeCount":102},[],{"trials":2572,"activeCount":102},[],{"trials":2574,"activeCount":102},[2575],{"nctId":2576,"briefTitle":2577,"status":256,"phases":2578,"primaryCompletion":353,"start":2579,"enrollment":2580,"conditions":2581,"interventions":2582},"NCT02534818","Different Fluorescein Sodium Dosage for the Detection of Gastric Intestinal Metaplasia",[93],"2015-06",180,[24],[2563,2583],"conventional fluorescein sodium dosage 0.1ml\u002Fkg",{"trials":2585,"activeCount":102},[],{"intervention":2583,"totalTrials":98,"cells":2587},{"EARLY_PHASE1":2588,"PHASE1":2590,"PHASE2":2592,"PHASE3":2594,"PHASE4":2596,"NA":2602},{"trials":2589,"activeCount":102},[],{"trials":2591,"activeCount":102},[],{"trials":2593,"activeCount":102},[],{"trials":2595,"activeCount":102},[],{"trials":2597,"activeCount":102},[2598],{"nctId":2576,"briefTitle":2577,"status":256,"phases":2599,"primaryCompletion":353,"start":2579,"enrollment":2580,"conditions":2600,"interventions":2601},[93],[24],[2563,2583],{"trials":2603,"activeCount":102},[],{"intervention":2605,"totalTrials":98,"cells":2606},"esomeprazole, amoxicillin, furazolidone，tetracycline",{"EARLY_PHASE1":2607,"PHASE1":2609,"PHASE2":2611,"PHASE3":2613,"PHASE4":2615,"NA":2625},{"trials":2608,"activeCount":102},[],{"trials":2610,"activeCount":102},[],{"trials":2612,"activeCount":102},[],{"trials":2614,"activeCount":102},[],{"trials":2616,"activeCount":102},[2617],{"nctId":2618,"briefTitle":2619,"status":256,"phases":2620,"primaryCompletion":1398,"completion":2621,"start":2622,"enrollment":261,"conditions":2623,"interventions":2624},"NCT03726099","Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection",[93],"2020-12-30","2019-03-15",[16],[2605],{"trials":2626,"activeCount":102},[],{"intervention":2628,"totalTrials":98,"cells":2629},"14-day high-dose Tegoprazan Dual Therapy",{"EARLY_PHASE1":2630,"PHASE1":2632,"PHASE2":2634,"PHASE3":2636,"PHASE4":2638,"NA":2649},{"trials":2631,"activeCount":102},[],{"trials":2633,"activeCount":102},[],{"trials":2635,"activeCount":102},[],{"trials":2637,"activeCount":102},[],{"trials":2639,"activeCount":102},[2640],{"nctId":2641,"briefTitle":2642,"status":256,"phases":2643,"primaryCompletion":2644,"completion":1790,"start":2645,"enrollment":2646,"conditions":2647,"interventions":2648},"NCT05438550","14-day Double Therapy Versus Bismuth Quadruple Therapy in First-line Treatment of Helicobacter Pylori Infection",[93],"2023-12-20","2023-02-14",258,[16],[2628],{"trials":2650,"activeCount":102},[],{"intervention":2652,"totalTrials":98,"cells":2653},"Tetracyclin",{"EARLY_PHASE1":2654,"PHASE1":2656,"PHASE2":2658,"PHASE3":2660,"PHASE4":2662,"NA":2673},{"trials":2655,"activeCount":102},[],{"trials":2657,"activeCount":102},[],{"trials":2659,"activeCount":102},[],{"trials":2661,"activeCount":102},[],{"trials":2663,"activeCount":102},[2664],{"nctId":2665,"briefTitle":2666,"status":256,"phases":2667,"primaryCompletion":1026,"completion":2668,"start":2669,"enrollment":2670,"conditions":2671,"interventions":2672},"NCT05432115","Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy of Different Tetracycline Doses and Frequencies.",[93],"2023-10","2022-06-25",407,[16],[2652],{"trials":2674,"activeCount":102},[],{"intervention":2676,"totalTrials":98,"cells":2677},"susceptibility guided therapy",{"EARLY_PHASE1":2678,"PHASE1":2680,"PHASE2":2682,"PHASE3":2684,"PHASE4":2686,"NA":2698},{"trials":2679,"activeCount":102},[],{"trials":2681,"activeCount":102},[],{"trials":2683,"activeCount":102},[],{"trials":2685,"activeCount":102},[],{"trials":2687,"activeCount":102},[2688],{"nctId":2689,"briefTitle":2690,"status":256,"phases":2691,"primaryCompletion":2692,"completion":2693,"start":1421,"enrollment":1102,"conditions":2694,"interventions":2695},"NCT03565484","Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the Rescue Treatment of Helicobacter Pylori Infection",[93],"2020-05-30","2020-06-30",[16],[2676,2696,2697],"personal medication history guided therapy","salvage treatment for failed eradication",{"trials":2699,"activeCount":102},[],{"intervention":2696,"totalTrials":98,"cells":2701},{"EARLY_PHASE1":2702,"PHASE1":2704,"PHASE2":2706,"PHASE3":2708,"PHASE4":2710,"NA":2716},{"trials":2703,"activeCount":102},[],{"trials":2705,"activeCount":102},[],{"trials":2707,"activeCount":102},[],{"trials":2709,"activeCount":102},[],{"trials":2711,"activeCount":102},[2712],{"nctId":2689,"briefTitle":2690,"status":256,"phases":2713,"primaryCompletion":2692,"completion":2693,"start":1421,"enrollment":1102,"conditions":2714,"interventions":2715},[93],[16],[2676,2696,2697],{"trials":2717,"activeCount":102},[],{"intervention":2697,"totalTrials":98,"cells":2719},{"EARLY_PHASE1":2720,"PHASE1":2722,"PHASE2":2724,"PHASE3":2726,"PHASE4":2728,"NA":2734},{"trials":2721,"activeCount":102},[],{"trials":2723,"activeCount":102},[],{"trials":2725,"activeCount":102},[],{"trials":2727,"activeCount":102},[],{"trials":2729,"activeCount":102},[2730],{"nctId":2689,"briefTitle":2690,"status":256,"phases":2731,"primaryCompletion":2692,"completion":2693,"start":1421,"enrollment":1102,"conditions":2732,"interventions":2733},[93],[16],[2676,2696,2697],{"trials":2735,"activeCount":102},[],{"intervention":1127,"totalTrials":98,"cells":2737},{"EARLY_PHASE1":2738,"PHASE1":2740,"PHASE2":2742,"PHASE3":2744,"PHASE4":2746,"NA":2752},{"trials":2739,"activeCount":102},[],{"trials":2741,"activeCount":102},[],{"trials":2743,"activeCount":102},[],{"trials":2745,"activeCount":102},[],{"trials":2747,"activeCount":102},[2748],{"nctId":1119,"briefTitle":1120,"status":225,"phases":2749,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":1124,"conditions":2750,"interventions":2751},[93],[16],[1015,1127,1128,1018,1019,1129],{"trials":2753,"activeCount":102},[],{"intervention":1128,"totalTrials":98,"cells":2755},{"EARLY_PHASE1":2756,"PHASE1":2758,"PHASE2":2760,"PHASE3":2762,"PHASE4":2764,"NA":2770},{"trials":2757,"activeCount":102},[],{"trials":2759,"activeCount":102},[],{"trials":2761,"activeCount":102},[],{"trials":2763,"activeCount":102},[],{"trials":2765,"activeCount":102},[2766],{"nctId":1119,"briefTitle":1120,"status":225,"phases":2767,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":1124,"conditions":2768,"interventions":2769},[93],[16],[1015,1127,1128,1018,1019,1129],{"trials":2771,"activeCount":102},[],{"intervention":1129,"totalTrials":98,"cells":2773},{"EARLY_PHASE1":2774,"PHASE1":2776,"PHASE2":2778,"PHASE3":2780,"PHASE4":2782,"NA":2788},{"trials":2775,"activeCount":102},[],{"trials":2777,"activeCount":102},[],{"trials":2779,"activeCount":102},[],{"trials":2781,"activeCount":102},[],{"trials":2783,"activeCount":102},[2784],{"nctId":1119,"briefTitle":1120,"status":225,"phases":2785,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":1124,"conditions":2786,"interventions":2787},[93],[16],[1015,1127,1128,1018,1019,1129],{"trials":2789,"activeCount":102},[],{"intervention":2791,"totalTrials":972,"cells":2792},"rhTPO",{"EARLY_PHASE1":2793,"PHASE1":2795,"PHASE2":2797,"PHASE3":2799,"PHASE4":2834,"NA":2836},{"trials":2794,"activeCount":102},[],{"trials":2796,"activeCount":102},[],{"trials":2798,"activeCount":102},[],{"trials":2800,"activeCount":102},[2801,2808,2818,2826],{"nctId":2802,"briefTitle":2803,"status":225,"phases":2804,"primaryCompletion":353,"completion":2275,"start":389,"enrollment":12,"conditions":2805,"interventions":2807},"NCT02391272","A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy",[92],[18,2806],"Pregnancy",[2791],{"nctId":2809,"briefTitle":2810,"status":256,"phases":2811,"primaryCompletion":1509,"completion":2812,"start":2813,"enrollment":746,"conditions":2814,"interventions":2817},"NCT02244658","Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia",[92],"2017-08","2014-09",[2815,232,2816],"Antineoplastic Adverse Reaction","Acute Myelocytic Leukemia",[2791],{"nctId":2819,"briefTitle":2820,"status":238,"phases":2821,"primaryCompletion":2822,"start":340,"enrollment":102,"conditions":2823,"interventions":2824},"NCT02203422","A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant\u002FRelapsed Immune Thrombocytopenia （ITP）",[92],"2015-07",[18],[2825,2791],"Cyclosporin A",{"nctId":2827,"briefTitle":2828,"status":256,"phases":2829,"primaryCompletion":260,"completion":2830,"start":2831,"enrollment":304,"conditions":2832,"interventions":2833},"NCT02270801","Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy",[92],"2017-04","2014-10",[18,2806],[2791],{"trials":2835,"activeCount":102},[],{"trials":2837,"activeCount":102},[],{"intervention":297,"totalTrials":405,"cells":2839},{"EARLY_PHASE1":2840,"PHASE1":2842,"PHASE2":2844,"PHASE3":2864,"PHASE4":2870,"NA":2872},{"trials":2841,"activeCount":102},[],{"trials":2843,"activeCount":102},[],{"trials":2845,"activeCount":102},[2846,2856],{"nctId":2847,"briefTitle":2848,"status":256,"phases":2849,"primaryCompletion":1490,"completion":2850,"start":2851,"enrollment":900,"conditions":2852,"interventions":2854},"NCT03045510","Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent",[91],"2020-07-30","2016-12-01",[2853],"Myelodysplastic Syndromes",[2855],"decitabine",{"nctId":2857,"briefTitle":2858,"status":225,"phases":2859,"primaryCompletion":2860,"completion":259,"start":270,"enrollment":2861,"conditions":2862,"interventions":2863},"NCT01568333","A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia",[91],"2017-10",45,[18],[297],{"trials":2865,"activeCount":102},[2866],{"nctId":288,"briefTitle":289,"status":256,"phases":2867,"primaryCompletion":291,"completion":292,"start":293,"enrollment":166,"conditions":2868,"interventions":2869},[92],[295,18],[297,72],{"trials":2871,"activeCount":102},[],{"trials":2873,"activeCount":102},[],{"intervention":1051,"totalTrials":762,"cells":2875},{"EARLY_PHASE1":2876,"PHASE1":2878,"PHASE2":2880,"PHASE3":2889,"PHASE4":2895,"NA":2897},{"trials":2877,"activeCount":102},[],{"trials":2879,"activeCount":102},[],{"trials":2881,"activeCount":102},[2882],{"nctId":2883,"briefTitle":2884,"status":256,"phases":2885,"primaryCompletion":1508,"completion":1508,"start":260,"enrollment":2886,"conditions":2887,"interventions":2888},"NCT03013114","A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP)",[91],20,[18],[1051],{"trials":2890,"activeCount":102},[2891],{"nctId":1044,"briefTitle":1045,"status":256,"phases":2892,"primaryCompletion":1047,"completion":360,"start":1048,"enrollment":166,"conditions":2893,"interventions":2894},[92],[18,295],[1033,1051],{"trials":2896,"activeCount":102},[],{"trials":2898,"activeCount":102},[],{"intervention":286,"totalTrials":98,"cells":2900},{"EARLY_PHASE1":2901,"PHASE1":2903,"PHASE2":2905,"PHASE3":2907,"PHASE4":2913,"NA":2915},{"trials":2902,"activeCount":102},[],{"trials":2904,"activeCount":102},[],{"trials":2906,"activeCount":102},[],{"trials":2908,"activeCount":102},[2909],{"nctId":278,"briefTitle":279,"status":238,"phases":2910,"primaryCompletion":240,"start":281,"enrollment":102,"conditions":2911,"interventions":2912},[92],[283,284],[286,72],{"trials":2914,"activeCount":102},[],{"trials":2916,"activeCount":102},[],{"intervention":2918,"totalTrials":98,"cells":2919},"Dabrafenib",{"EARLY_PHASE1":2920,"PHASE1":2922,"PHASE2":2924,"PHASE3":2926,"PHASE4":2937,"NA":2939},{"trials":2921,"activeCount":102},[],{"trials":2923,"activeCount":102},[],{"trials":2925,"activeCount":102},[],{"trials":2927,"activeCount":102},[2928],{"nctId":2929,"briefTitle":2930,"status":256,"phases":2931,"primaryCompletion":2932,"completion":62,"start":2933,"enrollment":28,"conditions":2934,"interventions":2936},"NCT06264778","Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma",[92],"2025-11-01","2024-03-01",[2935],"Ameloblastoma",[2918],{"trials":2938,"activeCount":102},[],{"trials":2940,"activeCount":102},[],{"intervention":2942,"totalTrials":98,"cells":2943},"DEX Combined With RTX, CSA and IVIG",{"EARLY_PHASE1":2944,"PHASE1":2946,"PHASE2":2948,"PHASE3":2950,"PHASE4":2960,"NA":2962},{"trials":2945,"activeCount":102},[],{"trials":2947,"activeCount":102},[],{"trials":2949,"activeCount":102},[],{"trials":2951,"activeCount":102},[2952],{"nctId":2953,"briefTitle":2954,"status":256,"phases":2955,"primaryCompletion":2956,"completion":2957,"start":2275,"enrollment":2149,"conditions":2958,"interventions":2959},"NCT02834468","DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients",[92],"2018-07","2018-12",[18],[2942],{"trials":2961,"activeCount":102},[],{"trials":2963,"activeCount":102},[],{"intervention":439,"totalTrials":98,"cells":2965},{"EARLY_PHASE1":2966,"PHASE1":2968,"PHASE2":2970,"PHASE3":2972,"PHASE4":2978,"NA":2980},{"trials":2967,"activeCount":102},[],{"trials":2969,"activeCount":102},[],{"trials":2971,"activeCount":102},[],{"trials":2973,"activeCount":102},[2974],{"nctId":429,"briefTitle":430,"status":256,"phases":2975,"primaryCompletion":432,"completion":433,"start":434,"enrollment":435,"conditions":2976,"interventions":2977},[92],[18],[438,439],{"trials":2979,"activeCount":102},[],{"trials":2981,"activeCount":102},[],{"intervention":308,"totalTrials":98,"cells":2983},{"EARLY_PHASE1":2984,"PHASE1":2986,"PHASE2":2988,"PHASE3":2990,"PHASE4":2996,"NA":2998},{"trials":2985,"activeCount":102},[],{"trials":2987,"activeCount":102},[],{"trials":2989,"activeCount":102},[],{"trials":2991,"activeCount":102},[2992],{"nctId":299,"briefTitle":300,"status":256,"phases":2993,"primaryCompletion":292,"completion":302,"start":303,"enrollment":304,"conditions":2994,"interventions":2995},[91,92],[18,306],[308,309,72],{"trials":2997,"activeCount":102},[],{"trials":2999,"activeCount":102},[],{"intervention":309,"totalTrials":98,"cells":3001},{"EARLY_PHASE1":3002,"PHASE1":3004,"PHASE2":3006,"PHASE3":3008,"PHASE4":3014,"NA":3016},{"trials":3003,"activeCount":102},[],{"trials":3005,"activeCount":102},[],{"trials":3007,"activeCount":102},[],{"trials":3009,"activeCount":102},[3010],{"nctId":299,"briefTitle":300,"status":256,"phases":3011,"primaryCompletion":292,"completion":302,"start":303,"enrollment":304,"conditions":3012,"interventions":3013},[91,92],[18,306],[308,309,72],{"trials":3015,"activeCount":102},[],{"trials":3017,"activeCount":102},[],{"intervention":2825,"totalTrials":98,"cells":3019},{"EARLY_PHASE1":3020,"PHASE1":3022,"PHASE2":3024,"PHASE3":3026,"PHASE4":3032,"NA":3034},{"trials":3021,"activeCount":102},[],{"trials":3023,"activeCount":102},[],{"trials":3025,"activeCount":102},[],{"trials":3027,"activeCount":102},[3028],{"nctId":2819,"briefTitle":2820,"status":238,"phases":3029,"primaryCompletion":2822,"start":340,"enrollment":102,"conditions":3030,"interventions":3031},[92],[18],[2825,2791],{"trials":3033,"activeCount":102},[],{"trials":3035,"activeCount":102},[],{"intervention":328,"totalTrials":98,"cells":3037},{"EARLY_PHASE1":3038,"PHASE1":3040,"PHASE2":3042,"PHASE3":3044,"PHASE4":3050,"NA":3052},{"trials":3039,"activeCount":102},[],{"trials":3041,"activeCount":102},[],{"trials":3043,"activeCount":102},[],{"trials":3045,"activeCount":102},[3046],{"nctId":321,"briefTitle":322,"status":238,"phases":3047,"primaryCompletion":324,"completion":241,"start":325,"enrollment":102,"conditions":3048,"interventions":3049},[92],[283,284],[328,72],{"trials":3051,"activeCount":102},[],{"trials":3053,"activeCount":102},[],{"intervention":1068,"totalTrials":98,"cells":3055},{"EARLY_PHASE1":3056,"PHASE1":3058,"PHASE2":3060,"PHASE3":3062,"PHASE4":3068,"NA":3070},{"trials":3057,"activeCount":102},[],{"trials":3059,"activeCount":102},[],{"trials":3061,"activeCount":102},[],{"trials":3063,"activeCount":102},[3064],{"nctId":1060,"briefTitle":1061,"status":225,"phases":3065,"primaryCompletion":314,"completion":1063,"start":1064,"enrollment":1065,"conditions":3066,"interventions":3067},[92],[283,284],[1068,1033],{"trials":3069,"activeCount":102},[],{"trials":3071,"activeCount":102},[],{"intervention":345,"totalTrials":98,"cells":3073},{"EARLY_PHASE1":3074,"PHASE1":3076,"PHASE2":3078,"PHASE3":3080,"PHASE4":3086,"NA":3088},{"trials":3075,"activeCount":102},[],{"trials":3077,"activeCount":102},[],{"trials":3079,"activeCount":102},[],{"trials":3081,"activeCount":102},[3082],{"nctId":337,"briefTitle":338,"status":225,"phases":3083,"primaryCompletion":340,"completion":341,"start":325,"enrollment":342,"conditions":3084,"interventions":3085},[92],[283,284],[345,72],{"trials":3087,"activeCount":102},[],{"trials":3089,"activeCount":102},[],{"intervention":3091,"totalTrials":762,"cells":3092},"Chidamide",{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3097,"PHASE3":3118,"PHASE4":3120,"NA":3122},{"trials":3094,"activeCount":102},[],{"trials":3096,"activeCount":102},[],{"trials":3098,"activeCount":102},[3099,3109],{"nctId":3100,"briefTitle":3101,"status":256,"phases":3102,"primaryCompletion":3103,"completion":3104,"start":3105,"enrollment":2149,"conditions":3106,"interventions":3107},"NCT05411874","A Multicenter Randomized Open-label Study of Chidamide Plus HD-DEX Versus HD-DEX in ITP",[91],"2023-10-30","2024-10-30","2022-10-01",[232],[3091,3108],"HD-DXM",{"nctId":3110,"briefTitle":3111,"status":225,"phases":3112,"primaryCompletion":3113,"completion":3114,"start":562,"enrollment":3115,"conditions":3116,"interventions":3117},"NCT03838354","A Clinical Trial of Chidamide in the Management of Refractory ITP",[90,91],"2022-09-01","2023-09-01",61,[232],[3091,3091],{"trials":3119,"activeCount":102},[],{"trials":3121,"activeCount":102},[],{"trials":3123,"activeCount":102},[],{"intervention":3125,"totalTrials":98,"cells":3126},"hetrombopag 5mg po qd",{"EARLY_PHASE1":3127,"PHASE1":3129,"PHASE2":3131,"PHASE3":3143,"PHASE4":3145,"NA":3147},{"trials":3128,"activeCount":102},[],{"trials":3130,"activeCount":102},[],{"trials":3132,"activeCount":102},[3133],{"nctId":3134,"briefTitle":3135,"status":256,"phases":3136,"primaryCompletion":3137,"completion":187,"start":3138,"enrollment":2149,"conditions":3139,"interventions":3141},"NCT05943691","High-dose Dexamethasone Plus Hetrombopag vs High-dose Dexamethasone Alone as Frontline Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial",[91],"2024-07-10","2023-09-15",[3140],"ITP - Immune Thrombocytopenia",[3125,3142],"High-dose Dexamethasone",{"trials":3144,"activeCount":102},[],{"trials":3146,"activeCount":102},[],{"trials":3148,"activeCount":102},[],{"intervention":3142,"totalTrials":98,"cells":3150},{"EARLY_PHASE1":3151,"PHASE1":3153,"PHASE2":3155,"PHASE3":3161,"PHASE4":3163,"NA":3165},{"trials":3152,"activeCount":102},[],{"trials":3154,"activeCount":102},[],{"trials":3156,"activeCount":102},[3157],{"nctId":3134,"briefTitle":3135,"status":256,"phases":3158,"primaryCompletion":3137,"completion":187,"start":3138,"enrollment":2149,"conditions":3159,"interventions":3160},[91],[3140],[3125,3142],{"trials":3162,"activeCount":102},[],{"trials":3164,"activeCount":102},[],{"trials":3166,"activeCount":102},[],{"intervention":234,"totalTrials":98,"cells":3168},{"EARLY_PHASE1":3169,"PHASE1":3171,"PHASE2":3173,"PHASE3":3179,"PHASE4":3181,"NA":3183},{"trials":3170,"activeCount":102},[],{"trials":3172,"activeCount":102},[],{"trials":3174,"activeCount":102},[3175],{"nctId":223,"briefTitle":224,"status":225,"phases":3176,"primaryCompletion":227,"completion":228,"start":229,"enrollment":230,"conditions":3177,"interventions":3178},[91],[232],[234,72],{"trials":3180,"activeCount":102},[],{"trials":3182,"activeCount":102},[],{"trials":3184,"activeCount":102},[],{"intervention":3186,"totalTrials":98,"cells":3187},"albumin-bound paclitaxe combined with bevacizumab biosimilar",{"EARLY_PHASE1":3188,"PHASE1":3190,"PHASE2":3192,"PHASE3":3202,"PHASE4":3204,"NA":3206},{"trials":3189,"activeCount":102},[],{"trials":3191,"activeCount":102},[],{"trials":3193,"activeCount":102},[3194],{"nctId":3195,"briefTitle":3196,"status":256,"phases":3197,"primaryCompletion":1790,"completion":2491,"start":3198,"enrollment":230,"conditions":3199,"interventions":3201},"NCT04670978","Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer",[91],"2021-03-31",[3200],"Objective Response Rate",[3186],{"trials":3203,"activeCount":102},[],{"trials":3205,"activeCount":102},[],{"trials":3207,"activeCount":102},[],{"intervention":244,"totalTrials":98,"cells":3209},{"EARLY_PHASE1":3210,"PHASE1":3212,"PHASE2":3214,"PHASE3":3220,"PHASE4":3222,"NA":3224},{"trials":3211,"activeCount":102},[],{"trials":3213,"activeCount":102},[],{"trials":3215,"activeCount":102},[3216],{"nctId":236,"briefTitle":237,"status":238,"phases":3217,"primaryCompletion":240,"start":241,"enrollment":102,"conditions":3218,"interventions":3219},[91],[18],[72,244],{"trials":3221,"activeCount":102},[],{"trials":3223,"activeCount":102},[],{"trials":3225,"activeCount":102},[],{"intervention":3227,"totalTrials":98,"cells":3228},"AraC",{"EARLY_PHASE1":3229,"PHASE1":3231,"PHASE2":3233,"PHASE3":3246,"PHASE4":3248,"NA":3250},{"trials":3230,"activeCount":102},[],{"trials":3232,"activeCount":102},[],{"trials":3234,"activeCount":102},[3235],{"nctId":3236,"briefTitle":3237,"status":256,"phases":3238,"primaryCompletion":2535,"completion":3239,"start":260,"enrollment":1389,"conditions":3240,"interventions":3242},"NCT03045627","Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients",[91],"2020-07",[3241],"Acute Myeloid Leukemia",[3227,3243,3244,3245],"Aclarubicin","Peg-G-CSF","G-CSF",{"trials":3247,"activeCount":102},[],{"trials":3249,"activeCount":102},[],{"trials":3251,"activeCount":102},[],{"intervention":3243,"totalTrials":98,"cells":3253},{"EARLY_PHASE1":3254,"PHASE1":3256,"PHASE2":3258,"PHASE3":3264,"PHASE4":3266,"NA":3268},{"trials":3255,"activeCount":102},[],{"trials":3257,"activeCount":102},[],{"trials":3259,"activeCount":102},[3260],{"nctId":3236,"briefTitle":3237,"status":256,"phases":3261,"primaryCompletion":2535,"completion":3239,"start":260,"enrollment":1389,"conditions":3262,"interventions":3263},[91],[3241],[3227,3243,3244,3245],{"trials":3265,"activeCount":102},[],{"trials":3267,"activeCount":102},[],{"trials":3269,"activeCount":102},[],{"intervention":3244,"totalTrials":98,"cells":3271},{"EARLY_PHASE1":3272,"PHASE1":3274,"PHASE2":3276,"PHASE3":3282,"PHASE4":3284,"NA":3286},{"trials":3273,"activeCount":102},[],{"trials":3275,"activeCount":102},[],{"trials":3277,"activeCount":102},[3278],{"nctId":3236,"briefTitle":3237,"status":256,"phases":3279,"primaryCompletion":2535,"completion":3239,"start":260,"enrollment":1389,"conditions":3280,"interventions":3281},[91],[3241],[3227,3243,3244,3245],{"trials":3283,"activeCount":102},[],{"trials":3285,"activeCount":102},[],{"trials":3287,"activeCount":102},[],{"intervention":3245,"totalTrials":98,"cells":3289},{"EARLY_PHASE1":3290,"PHASE1":3292,"PHASE2":3294,"PHASE3":3300,"PHASE4":3302,"NA":3304},{"trials":3291,"activeCount":102},[],{"trials":3293,"activeCount":102},[],{"trials":3295,"activeCount":102},[3296],{"nctId":3236,"briefTitle":3237,"status":256,"phases":3297,"primaryCompletion":2535,"completion":3239,"start":260,"enrollment":1389,"conditions":3298,"interventions":3299},[91],[3241],[3227,3243,3244,3245],{"trials":3301,"activeCount":102},[],{"trials":3303,"activeCount":102},[],{"trials":3305,"activeCount":102},[],{"intervention":3108,"totalTrials":98,"cells":3307},{"EARLY_PHASE1":3308,"PHASE1":3310,"PHASE2":3312,"PHASE3":3318,"PHASE4":3320,"NA":3322},{"trials":3309,"activeCount":102},[],{"trials":3311,"activeCount":102},[],{"trials":3313,"activeCount":102},[3314],{"nctId":3100,"briefTitle":3101,"status":256,"phases":3315,"primaryCompletion":3103,"completion":3104,"start":3105,"enrollment":2149,"conditions":3316,"interventions":3317},[91],[232],[3091,3108],{"trials":3319,"activeCount":102},[],{"trials":3321,"activeCount":102},[],{"trials":3323,"activeCount":102},[],{"intervention":264,"totalTrials":98,"cells":3325},{"EARLY_PHASE1":3326,"PHASE1":3328,"PHASE2":3330,"PHASE3":3336,"PHASE4":3338,"NA":3340},{"trials":3327,"activeCount":102},[],{"trials":3329,"activeCount":102},[],{"trials":3331,"activeCount":102},[3332],{"nctId":254,"briefTitle":255,"status":256,"phases":3333,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":3334,"interventions":3335},[91],[18],[264,72],{"trials":3337,"activeCount":102},[],{"trials":3339,"activeCount":102},[],{"trials":3341,"activeCount":102},[],{"intervention":3343,"totalTrials":98,"cells":3344},"MSC",{"EARLY_PHASE1":3345,"PHASE1":3347,"PHASE2":3349,"PHASE3":3359,"PHASE4":3361,"NA":3363},{"trials":3346,"activeCount":102},[],{"trials":3348,"activeCount":102},[],{"trials":3350,"activeCount":102},[3351],{"nctId":3352,"briefTitle":3353,"status":256,"phases":3354,"primaryCompletion":314,"completion":340,"start":3355,"enrollment":304,"conditions":3356,"interventions":3358},"NCT01413035","Safety and Efficacy Study of Umbilical Cord\u002FPlacenta-Derived Mesenchymal Stem Cells to Treat Type 2 Diabetes",[90,91],"2011-07",[3357],"Type 2 Diabetes",[3343],{"trials":3360,"activeCount":102},[],{"trials":3362,"activeCount":102},[],{"trials":3364,"activeCount":102},[],{"intervention":3366,"totalTrials":98,"cells":3367},"Orelabrutinib",{"EARLY_PHASE1":3368,"PHASE1":3370,"PHASE2":3372,"PHASE3":3382,"PHASE4":3384,"NA":3386},{"trials":3369,"activeCount":102},[],{"trials":3371,"activeCount":102},[],{"trials":3373,"activeCount":102},[3374],{"nctId":3375,"briefTitle":3376,"status":256,"phases":3377,"primaryCompletion":1790,"completion":417,"start":3378,"enrollment":1207,"conditions":3379,"interventions":3381},"NCT05020288","A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP",[91],"2021-09-01",[18,3380],"Bruton's Tyrosine Kinase",[3366],{"trials":3383,"activeCount":102},[],{"trials":3385,"activeCount":102},[],{"trials":3387,"activeCount":102},[],{"intervention":3389,"totalTrials":98,"cells":3390},"fluorescein sodium 0.01ml\u002Fkg",{"EARLY_PHASE1":3391,"PHASE1":3393,"PHASE2":3395,"PHASE3":3409,"PHASE4":3411,"NA":3413},{"trials":3392,"activeCount":102},[],{"trials":3394,"activeCount":102},[],{"trials":3396,"activeCount":102},[3397],{"nctId":3398,"briefTitle":3399,"status":256,"phases":3400,"primaryCompletion":1767,"completion":1767,"start":3401,"enrollment":3402,"conditions":3403,"interventions":3405},"NCT02519920","Lower Fluorescein Sodium Dose on Confocal Laser Endoscopy Image Quality and Yellow Discoloration of the Skin",[91],"2015-04",63,[1494,3404],"Skin Discoloration",[3389,3406,3407,3408],"fluorescein sodium 0.02ml\u002Fkg","fluorescein sodium 0.05ml\u002Fkg","fluorescein sodium 0.1ml\u002Fkg",{"trials":3410,"activeCount":102},[],{"trials":3412,"activeCount":102},[],{"trials":3414,"activeCount":102},[],{"intervention":3406,"totalTrials":98,"cells":3416},{"EARLY_PHASE1":3417,"PHASE1":3419,"PHASE2":3421,"PHASE3":3427,"PHASE4":3429,"NA":3431},{"trials":3418,"activeCount":102},[],{"trials":3420,"activeCount":102},[],{"trials":3422,"activeCount":102},[3423],{"nctId":3398,"briefTitle":3399,"status":256,"phases":3424,"primaryCompletion":1767,"completion":1767,"start":3401,"enrollment":3402,"conditions":3425,"interventions":3426},[91],[1494,3404],[3389,3406,3407,3408],{"trials":3428,"activeCount":102},[],{"trials":3430,"activeCount":102},[],{"trials":3432,"activeCount":102},[],{"intervention":3407,"totalTrials":98,"cells":3434},{"EARLY_PHASE1":3435,"PHASE1":3437,"PHASE2":3439,"PHASE3":3445,"PHASE4":3447,"NA":3449},{"trials":3436,"activeCount":102},[],{"trials":3438,"activeCount":102},[],{"trials":3440,"activeCount":102},[3441],{"nctId":3398,"briefTitle":3399,"status":256,"phases":3442,"primaryCompletion":1767,"completion":1767,"start":3401,"enrollment":3402,"conditions":3443,"interventions":3444},[91],[1494,3404],[3389,3406,3407,3408],{"trials":3446,"activeCount":102},[],{"trials":3448,"activeCount":102},[],{"trials":3450,"activeCount":102},[],{"intervention":3408,"totalTrials":98,"cells":3452},{"EARLY_PHASE1":3453,"PHASE1":3455,"PHASE2":3457,"PHASE3":3463,"PHASE4":3465,"NA":3467},{"trials":3454,"activeCount":102},[],{"trials":3456,"activeCount":102},[],{"trials":3458,"activeCount":102},[3459],{"nctId":3398,"briefTitle":3399,"status":256,"phases":3460,"primaryCompletion":1767,"completion":1767,"start":3401,"enrollment":3402,"conditions":3461,"interventions":3462},[91],[1494,3404],[3389,3406,3407,3408],{"trials":3464,"activeCount":102},[],{"trials":3466,"activeCount":102},[],{"trials":3468,"activeCount":102},[],{"intervention":3470,"totalTrials":98,"cells":3471},"Eltrombopag and Diacerein",{"EARLY_PHASE1":3472,"PHASE1":3474,"PHASE2":3476,"PHASE3":3487,"PHASE4":3489,"NA":3491},{"trials":3473,"activeCount":102},[],{"trials":3475,"activeCount":102},[],{"trials":3477,"activeCount":102},[3478],{"nctId":3479,"briefTitle":3480,"status":225,"phases":3481,"primaryCompletion":3482,"completion":3483,"start":3484,"enrollment":304,"conditions":3485,"interventions":3486},"NCT03754634","A Prospective, Open, Multicenter Clinical Trial of Eltrombopag Combined With Diacerein in Eltrombopag-inefficient or Relapsed ITP",[91],"2020-06-01","2020-11-01","2019-05-01",[232],[3470],{"trials":3488,"activeCount":102},[],{"trials":3490,"activeCount":102},[],{"trials":3492,"activeCount":102},[],{"intervention":3494,"totalTrials":98,"cells":3495},"Scopolamine Hydrobromide",{"EARLY_PHASE1":3496,"PHASE1":3498,"PHASE2":3511,"PHASE3":3513,"PHASE4":3515,"NA":3517},{"trials":3497,"activeCount":102},[],{"trials":3499,"activeCount":102},[3500],{"nctId":3501,"briefTitle":3502,"status":225,"phases":3503,"primaryCompletion":3504,"completion":2579,"start":3505,"enrollment":3506,"conditions":3507,"interventions":3509},"NCT02811341","The Application of Spasmolytic in PCLE Examination of Superior Gastrointestinal Endoscope",[90],"2015-02","2014-08",122,[3508],"Using Copolamine Butylbromide in Probe-based Confocal Laser Endomicroscopy for Gastroendoscopy Examination",[3494,3510],"normal saline",{"trials":3512,"activeCount":102},[],{"trials":3514,"activeCount":102},[],{"trials":3516,"activeCount":102},[],{"trials":3518,"activeCount":102},[],{"intervention":3520,"totalTrials":98,"cells":3521},"Probiotic",{"EARLY_PHASE1":3522,"PHASE1":3524,"PHASE2":3537,"PHASE3":3539,"PHASE4":3541,"NA":3543},{"trials":3523,"activeCount":102},[],{"trials":3525,"activeCount":102},[3526],{"nctId":3527,"briefTitle":3528,"status":256,"phases":3529,"primaryCompletion":2831,"completion":269,"start":1063,"enrollment":304,"conditions":3530,"interventions":3536},"NCT02169388","Intestinal Microflora in Colorectal Cancer (CRC) After Chemotherapy",[90],[3531,3532,3533,3534,3535],"Gastrointestinal Neoplasms","Colorectal Cancer","Effects of Chemotherapy","Tumor Immunity","Malnutrition",[3520],{"trials":3538,"activeCount":102},[],{"trials":3540,"activeCount":102},[],{"trials":3542,"activeCount":102},[],{"trials":3544,"activeCount":102},[],{"intervention":3546,"totalTrials":98,"cells":3547},"Probiotic Clostridium Butyricum",{"EARLY_PHASE1":3548,"PHASE1":3550,"PHASE2":3560,"PHASE3":3562,"PHASE4":3564,"NA":3566},{"trials":3549,"activeCount":102},[],{"trials":3551,"activeCount":102},[3552],{"nctId":3553,"briefTitle":3554,"status":225,"phases":3555,"primaryCompletion":270,"completion":1766,"start":340,"enrollment":3556,"conditions":3557,"interventions":3558},"NCT02254629","The Effects of Laxative-probiotic Sequential Treatment in the Irritable Bowel Syndrome Patients",[90],56,[33],[3546,3559],"Laxative Polyethylene Glycol",{"trials":3561,"activeCount":102},[],{"trials":3563,"activeCount":102},[],{"trials":3565,"activeCount":102},[],{"trials":3567,"activeCount":102},[],{"intervention":3559,"totalTrials":98,"cells":3569},{"EARLY_PHASE1":3570,"PHASE1":3572,"PHASE2":3578,"PHASE3":3580,"PHASE4":3582,"NA":3584},{"trials":3571,"activeCount":102},[],{"trials":3573,"activeCount":102},[3574],{"nctId":3553,"briefTitle":3554,"status":225,"phases":3575,"primaryCompletion":270,"completion":1766,"start":340,"enrollment":3556,"conditions":3576,"interventions":3577},[90],[33],[3546,3559],{"trials":3579,"activeCount":102},[],{"trials":3581,"activeCount":102},[],{"trials":3583,"activeCount":102},[],{"trials":3585,"activeCount":102},[],{"intervention":3587,"totalTrials":98,"cells":3588},"Probiotics",{"EARLY_PHASE1":3589,"PHASE1":3591,"PHASE2":3601,"PHASE3":3603,"PHASE4":3605,"NA":3607},{"trials":3590,"activeCount":102},[],{"trials":3592,"activeCount":102},[3593],{"nctId":3594,"briefTitle":3595,"status":225,"phases":3596,"primaryCompletion":1766,"completion":1766,"start":2813,"enrollment":3597,"conditions":3598,"interventions":3600},"NCT02771470","Intestinal Microflora in Lung Cancer After Chemotherapy",[90],41,[3599,3533,3534,3535],"Lung Cancer",[3587],{"trials":3602,"activeCount":102},[],{"trials":3604,"activeCount":102},[],{"trials":3606,"activeCount":102},[],{"trials":3608,"activeCount":102},[],{"intervention":3610,"totalTrials":98,"cells":3611},"Human umbilical cord-derived MSCs",{"EARLY_PHASE1":3612,"PHASE1":3614,"PHASE2":3624,"PHASE3":3626,"PHASE4":3628,"NA":3630},{"trials":3613,"activeCount":102},[],{"trials":3615,"activeCount":102},[3616],{"nctId":3617,"briefTitle":3618,"status":256,"phases":3619,"primaryCompletion":314,"completion":314,"start":3620,"enrollment":28,"conditions":3621,"interventions":3623},"NCT01420432","Safety and Efficacy Study of Umbilical Cord\u002FPlacenta-Derived Mesenchymal Stem Cells to Treat Ankylosing Spondylitis (AS)",[90],"2011-01",[3622],"Ankylosing Spondylitis",[3610],{"trials":3625,"activeCount":102},[],{"trials":3627,"activeCount":102},[],{"trials":3629,"activeCount":102},[],{"trials":3631,"activeCount":102},[],{"intervention":3633,"totalTrials":98,"cells":3634},"Acetic Acid",{"EARLY_PHASE1":3635,"PHASE1":3637,"PHASE2":3646,"PHASE3":3648,"PHASE4":3650,"NA":3652},{"trials":3636,"activeCount":102},[],{"trials":3638,"activeCount":102},[3639],{"nctId":3640,"briefTitle":3641,"status":256,"phases":3642,"primaryCompletion":3643,"start":2275,"enrollment":2149,"conditions":3644,"interventions":3645},"NCT02806115","The Efficacy of Severe Whitening and Delayed Fading in Acetic Acid-enhanced Endoscopy for Diagnosing Gastric Intestinal Metaplasia",[90],"2016-08",[24],[3633],{"trials":3647,"activeCount":102},[],{"trials":3649,"activeCount":102},[],{"trials":3651,"activeCount":102},[],{"trials":3653,"activeCount":102},[],{"intervention":3655,"totalTrials":98,"cells":3656},"CNCT19",{"EARLY_PHASE1":3657,"PHASE1":3668,"PHASE2":3670,"PHASE3":3672,"PHASE4":3674,"NA":3676},{"trials":3658,"activeCount":102},[3659],{"nctId":3660,"briefTitle":3661,"status":256,"phases":3662,"primaryCompletion":3239,"completion":3663,"start":3664,"enrollment":2886,"conditions":3665,"interventions":3667},"NCT04011293","A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies",[89],"2022-04","2019-07",[3666],"Relapsed or Refractory Hematological Malignancies",[3655],{"trials":3669,"activeCount":102},[],{"trials":3671,"activeCount":102},[],{"trials":3673,"activeCount":102},[],{"trials":3675,"activeCount":102},[],{"trials":3677,"activeCount":102},[],{"intervention":3679,"totalTrials":405,"cells":3680},"Polyethylene Glycol",{"EARLY_PHASE1":3681,"PHASE1":3683,"PHASE2":3685,"PHASE3":3687,"PHASE4":3689,"NA":3691},{"trials":3682,"activeCount":102},[],{"trials":3684,"activeCount":102},[],{"trials":3686,"activeCount":102},[],{"trials":3688,"activeCount":102},[],{"trials":3690,"activeCount":102},[],{"trials":3692,"activeCount":102},[3693,3704,3715],{"nctId":3694,"briefTitle":3695,"status":225,"phases":3696,"primaryCompletion":3697,"completion":3698,"start":3699,"enrollment":3700,"conditions":3701,"interventions":3703},"NCT03142854","Efficacy of Tailored Bowel Preparation Strategy Guided by a Predictive Model",[94],"2017-07-30","2017-08-30","2017-05-01",429,[1726,3702],"Colonoscopy",[3679,3679],{"nctId":3705,"briefTitle":3706,"status":256,"phases":3707,"primaryCompletion":3708,"completion":380,"start":3709,"enrollment":261,"conditions":3710,"interventions":3712},"NCT03495804","Evaluation of the Performance of Two Neutral Oral Contrast Agents in CT Enterography",[94],"2018-09","2017-11-01",[3711],"CTE",[3713,3714],"polyethylene glycol","mannitol",{"nctId":3716,"briefTitle":3717,"status":225,"phases":3718,"primaryCompletion":3719,"completion":3720,"start":3721,"enrollment":3700,"conditions":3722,"interventions":3723},"NCT03704571","A Predictive Model for Inadequate Bowel Preparation",[94],"2019-07-31","2019-08-30","2018-11-01",[36],[3679],{"intervention":3510,"totalTrials":762,"cells":3725},{"EARLY_PHASE1":3726,"PHASE1":3728,"PHASE2":3734,"PHASE3":3736,"PHASE4":3738,"NA":3740},{"trials":3727,"activeCount":102},[],{"trials":3729,"activeCount":102},[3730],{"nctId":3501,"briefTitle":3502,"status":225,"phases":3731,"primaryCompletion":3504,"completion":2579,"start":3505,"enrollment":3506,"conditions":3732,"interventions":3733},[90],[3508],[3494,3510],{"trials":3735,"activeCount":102},[],{"trials":3737,"activeCount":102},[],{"trials":3739,"activeCount":102},[],{"trials":3741,"activeCount":102},[3742],{"nctId":3743,"briefTitle":3744,"status":256,"phases":3745,"primaryCompletion":433,"completion":3746,"start":3747,"enrollment":1161,"conditions":3748,"interventions":3750},"NCT05179252","Shenfu Injection for Postoperative Delirium (SFI for POD)",[94],"2022-12-01","2022-02-01",[3749],"Postoperative Delirium",[3751,3510],"Shen-Fu",{"intervention":3753,"totalTrials":98,"cells":3754},"Polyethylene Glycol Recombinant Human Somatropin",{"EARLY_PHASE1":3755,"PHASE1":3757,"PHASE2":3759,"PHASE3":3761,"PHASE4":3763,"NA":3765},{"trials":3756,"activeCount":102},[],{"trials":3758,"activeCount":102},[],{"trials":3760,"activeCount":102},[],{"trials":3762,"activeCount":102},[],{"trials":3764,"activeCount":102},[],{"trials":3766,"activeCount":102},[3767],{"nctId":3768,"briefTitle":3769,"status":256,"phases":3770,"primaryCompletion":3771,"completion":3772,"start":291,"enrollment":166,"conditions":3773,"interventions":3775},"NCT04588844","Effect of Growth Hormone Injection on the IVF\u002FICSI Outcome of Patients With Poor Ovarian Reserve.",[94],"2022-03-20","2023-03-20",[3774],"Poor Ovarian Reserve",[3753],{"intervention":3777,"totalTrials":98,"cells":3778},"Avatrombopag",{"EARLY_PHASE1":3779,"PHASE1":3781,"PHASE2":3783,"PHASE3":3785,"PHASE4":3787,"NA":3789},{"trials":3780,"activeCount":102},[],{"trials":3782,"activeCount":102},[],{"trials":3784,"activeCount":102},[],{"trials":3786,"activeCount":102},[],{"trials":3788,"activeCount":102},[],{"trials":3790,"activeCount":102},[3791],{"nctId":3792,"briefTitle":3793,"status":256,"phases":3794,"primaryCompletion":361,"completion":3795,"start":360,"enrollment":1102,"conditions":3796,"interventions":3798},"NCT04949009","Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP)",[],"2022-03",[3797],"Primary Immune Thrombocytopenia",[3777],{"intervention":3800,"totalTrials":98,"cells":3801},"meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid",{"EARLY_PHASE1":3802,"PHASE1":3804,"PHASE2":3806,"PHASE3":3808,"PHASE4":3810,"NA":3812},{"trials":3803,"activeCount":102},[],{"trials":3805,"activeCount":102},[],{"trials":3807,"activeCount":102},[],{"trials":3809,"activeCount":102},[],{"trials":3811,"activeCount":102},[],{"trials":3813,"activeCount":102},[3814],{"nctId":3815,"briefTitle":3816,"status":256,"phases":3817,"primaryCompletion":3818,"completion":3819,"start":362,"enrollment":118,"conditions":3820,"interventions":3823},"NCT04771884","Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance",[],"2026-01-20","2026-03-20",[3821,3822],"Bacterial Meningitis","Augmented Renal Clearance",[3800],{"intervention":3825,"totalTrials":98,"cells":3826},"1500ml of 2.5% mannitol",{"EARLY_PHASE1":3827,"PHASE1":3829,"PHASE2":3831,"PHASE3":3833,"PHASE4":3835,"NA":3837},{"trials":3828,"activeCount":102},[],{"trials":3830,"activeCount":102},[],{"trials":3832,"activeCount":102},[],{"trials":3834,"activeCount":102},[],{"trials":3836,"activeCount":102},[],{"trials":3838,"activeCount":102},[3839],{"nctId":3840,"briefTitle":3841,"status":256,"phases":3842,"primaryCompletion":3843,"completion":3844,"start":3845,"enrollment":2580,"conditions":3846,"interventions":3847},"NCT03808649","Individualized Volume of Oral Contrast Agent in CT Enterography",[94],"2019-03-20","2019-07-20","2019-01-20",[3711],[3825,3848],"different volume of 2.5% mannitol",{"intervention":3848,"totalTrials":98,"cells":3850},{"EARLY_PHASE1":3851,"PHASE1":3853,"PHASE2":3855,"PHASE3":3857,"PHASE4":3859,"NA":3861},{"trials":3852,"activeCount":102},[],{"trials":3854,"activeCount":102},[],{"trials":3856,"activeCount":102},[],{"trials":3858,"activeCount":102},[],{"trials":3860,"activeCount":102},[],{"trials":3862,"activeCount":102},[3863],{"nctId":3840,"briefTitle":3841,"status":256,"phases":3864,"primaryCompletion":3843,"completion":3844,"start":3845,"enrollment":2580,"conditions":3865,"interventions":3866},[94],[3711],[3825,3848],{"intervention":3868,"totalTrials":98,"cells":3869},"Montelukast Chewable",{"EARLY_PHASE1":3870,"PHASE1":3872,"PHASE2":3874,"PHASE3":3876,"PHASE4":3878,"NA":3880},{"trials":3871,"activeCount":102},[],{"trials":3873,"activeCount":102},[],{"trials":3875,"activeCount":102},[],{"trials":3877,"activeCount":102},[],{"trials":3879,"activeCount":102},[],{"trials":3881,"activeCount":102},[3882],{"nctId":3883,"briefTitle":3884,"status":256,"phases":3885,"primaryCompletion":3886,"completion":3886,"start":3887,"enrollment":2149,"conditions":3888,"interventions":3890},"NCT03238560","The Population Pharmacokinetics of Montelukast in Infants and Children",[],"2018-06-01","2016-10-01",[3889],"Asthma",[3868],{"intervention":3892,"totalTrials":98,"cells":3893},"Pyrotinib+Trastuzumab+Docetaxel+Carboplatin",{"EARLY_PHASE1":3894,"PHASE1":3896,"PHASE2":3898,"PHASE3":3900,"PHASE4":3902,"NA":3904},{"trials":3895,"activeCount":102},[],{"trials":3897,"activeCount":102},[],{"trials":3899,"activeCount":102},[],{"trials":3901,"activeCount":102},[],{"trials":3903,"activeCount":102},[],{"trials":3905,"activeCount":102},[3906],{"nctId":3907,"briefTitle":3908,"status":256,"phases":3909,"primaryCompletion":1047,"completion":3910,"start":3911,"enrollment":3912,"conditions":3913,"interventions":3915},"NCT03847818","Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer",[94],"2021-02-28","2019-03-01",268,[3914],"HER2-positive Breast Cancer",[3892],{"intervention":3917,"totalTrials":98,"cells":3918},"Ioversol",{"EARLY_PHASE1":3919,"PHASE1":3921,"PHASE2":3923,"PHASE3":3925,"PHASE4":3927,"NA":3929},{"trials":3920,"activeCount":102},[],{"trials":3922,"activeCount":102},[],{"trials":3924,"activeCount":102},[],{"trials":3926,"activeCount":102},[],{"trials":3928,"activeCount":102},[],{"trials":3930,"activeCount":102},[3931],{"nctId":3932,"briefTitle":3933,"status":225,"phases":3934,"primaryCompletion":3935,"completion":3936,"start":745,"enrollment":3937,"conditions":3938,"interventions":3940},"NCT07391787","Low-acid Contrast Media for Preventing Post ERCP Pancreatitis",[],"2025-12-25","2026-01-15",3979,[3939],"Post-ERCP Acute Pancreatitis",[3917,3941,3942],"Iopromide","Iohexol",{"intervention":3941,"totalTrials":98,"cells":3944},{"EARLY_PHASE1":3945,"PHASE1":3947,"PHASE2":3949,"PHASE3":3951,"PHASE4":3953,"NA":3955},{"trials":3946,"activeCount":102},[],{"trials":3948,"activeCount":102},[],{"trials":3950,"activeCount":102},[],{"trials":3952,"activeCount":102},[],{"trials":3954,"activeCount":102},[],{"trials":3956,"activeCount":102},[3957],{"nctId":3932,"briefTitle":3933,"status":225,"phases":3958,"primaryCompletion":3935,"completion":3936,"start":745,"enrollment":3937,"conditions":3959,"interventions":3960},[],[3939],[3917,3941,3942],{"intervention":3942,"totalTrials":98,"cells":3962},{"EARLY_PHASE1":3963,"PHASE1":3965,"PHASE2":3967,"PHASE3":3969,"PHASE4":3971,"NA":3973},{"trials":3964,"activeCount":102},[],{"trials":3966,"activeCount":102},[],{"trials":3968,"activeCount":102},[],{"trials":3970,"activeCount":102},[],{"trials":3972,"activeCount":102},[],{"trials":3974,"activeCount":102},[3975],{"nctId":3932,"briefTitle":3933,"status":225,"phases":3976,"primaryCompletion":3935,"completion":3936,"start":745,"enrollment":3937,"conditions":3977,"interventions":3978},[],[3939],[3917,3941,3942],{"intervention":3980,"totalTrials":98,"cells":3981},"Cefuroxime",{"EARLY_PHASE1":3982,"PHASE1":3984,"PHASE2":3986,"PHASE3":3988,"PHASE4":3990,"NA":3992},{"trials":3983,"activeCount":102},[],{"trials":3985,"activeCount":102},[],{"trials":3987,"activeCount":102},[],{"trials":3989,"activeCount":102},[],{"trials":3991,"activeCount":102},[],{"trials":3993,"activeCount":102},[3994],{"nctId":3995,"briefTitle":3996,"status":256,"phases":3997,"primaryCompletion":3998,"completion":3999,"start":4000,"enrollment":2149,"conditions":4001,"interventions":4003},"NCT05388747","Population Pharmacokinetics, Effectiveness and Safety of Cefuroxime in Neonates",[],"2025-07-01","2025-12-01","2022-05-16",[4002],"Infectious Disease",[3980],{"intervention":4005,"totalTrials":98,"cells":4006},"Amoxicillin , Levofloxacin and Esomeprazole",{"EARLY_PHASE1":4007,"PHASE1":4009,"PHASE2":4011,"PHASE3":4013,"PHASE4":4015,"NA":4017},{"trials":4008,"activeCount":102},[],{"trials":4010,"activeCount":102},[],{"trials":4012,"activeCount":102},[],{"trials":4014,"activeCount":102},[],{"trials":4016,"activeCount":102},[],{"trials":4018,"activeCount":102},[4019],{"nctId":4020,"briefTitle":4021,"status":225,"phases":4022,"primaryCompletion":2105,"completion":4023,"start":1188,"enrollment":4024,"conditions":4025,"interventions":4026},"NCT04810793","The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure",[],"2022-06-30",820,[27],[4005,4027,4028,4029,4030,4031],"Amoxicillin , Furazolidone and Esomeprazole","Tetracycline , Furazolidone and Esomeprazole","Amoxicillin,Levofloxacin and Vonoprazan fumarate","Amoxicillin,Furazolidone and Vonoprazan fumarate","Tetracycline,Furazolidone and Vonoprazan fumarate",{"intervention":4027,"totalTrials":98,"cells":4033},{"EARLY_PHASE1":4034,"PHASE1":4036,"PHASE2":4038,"PHASE3":4040,"PHASE4":4042,"NA":4044},{"trials":4035,"activeCount":102},[],{"trials":4037,"activeCount":102},[],{"trials":4039,"activeCount":102},[],{"trials":4041,"activeCount":102},[],{"trials":4043,"activeCount":102},[],{"trials":4045,"activeCount":102},[4046],{"nctId":4020,"briefTitle":4021,"status":225,"phases":4047,"primaryCompletion":2105,"completion":4023,"start":1188,"enrollment":4024,"conditions":4048,"interventions":4049},[],[27],[4005,4027,4028,4029,4030,4031],{"intervention":4028,"totalTrials":98,"cells":4051},{"EARLY_PHASE1":4052,"PHASE1":4054,"PHASE2":4056,"PHASE3":4058,"PHASE4":4060,"NA":4062},{"trials":4053,"activeCount":102},[],{"trials":4055,"activeCount":102},[],{"trials":4057,"activeCount":102},[],{"trials":4059,"activeCount":102},[],{"trials":4061,"activeCount":102},[],{"trials":4063,"activeCount":102},[4064],{"nctId":4020,"briefTitle":4021,"status":225,"phases":4065,"primaryCompletion":2105,"completion":4023,"start":1188,"enrollment":4024,"conditions":4066,"interventions":4067},[],[27],[4005,4027,4028,4029,4030,4031],{"intervention":4029,"totalTrials":98,"cells":4069},{"EARLY_PHASE1":4070,"PHASE1":4072,"PHASE2":4074,"PHASE3":4076,"PHASE4":4078,"NA":4080},{"trials":4071,"activeCount":102},[],{"trials":4073,"activeCount":102},[],{"trials":4075,"activeCount":102},[],{"trials":4077,"activeCount":102},[],{"trials":4079,"activeCount":102},[],{"trials":4081,"activeCount":102},[4082],{"nctId":4020,"briefTitle":4021,"status":225,"phases":4083,"primaryCompletion":2105,"completion":4023,"start":1188,"enrollment":4024,"conditions":4084,"interventions":4085},[],[27],[4005,4027,4028,4029,4030,4031],{"intervention":4030,"totalTrials":98,"cells":4087},{"EARLY_PHASE1":4088,"PHASE1":4090,"PHASE2":4092,"PHASE3":4094,"PHASE4":4096,"NA":4098},{"trials":4089,"activeCount":102},[],{"trials":4091,"activeCount":102},[],{"trials":4093,"activeCount":102},[],{"trials":4095,"activeCount":102},[],{"trials":4097,"activeCount":102},[],{"trials":4099,"activeCount":102},[4100],{"nctId":4020,"briefTitle":4021,"status":225,"phases":4101,"primaryCompletion":2105,"completion":4023,"start":1188,"enrollment":4024,"conditions":4102,"interventions":4103},[],[27],[4005,4027,4028,4029,4030,4031],{"intervention":4031,"totalTrials":98,"cells":4105},{"EARLY_PHASE1":4106,"PHASE1":4108,"PHASE2":4110,"PHASE3":4112,"PHASE4":4114,"NA":4116},{"trials":4107,"activeCount":102},[],{"trials":4109,"activeCount":102},[],{"trials":4111,"activeCount":102},[],{"trials":4113,"activeCount":102},[],{"trials":4115,"activeCount":102},[],{"trials":4117,"activeCount":102},[4118],{"nctId":4020,"briefTitle":4021,"status":225,"phases":4119,"primaryCompletion":2105,"completion":4023,"start":1188,"enrollment":4024,"conditions":4120,"interventions":4121},[],[27],[4005,4027,4028,4029,4030,4031],{"intervention":4123,"totalTrials":98,"cells":4124},"Caspogunfin",{"EARLY_PHASE1":4125,"PHASE1":4127,"PHASE2":4129,"PHASE3":4131,"PHASE4":4133,"NA":4135},{"trials":4126,"activeCount":102},[],{"trials":4128,"activeCount":102},[],{"trials":4130,"activeCount":102},[],{"trials":4132,"activeCount":102},[],{"trials":4134,"activeCount":102},[],{"trials":4136,"activeCount":102},[4137],{"nctId":4138,"briefTitle":4139,"status":225,"phases":4140,"primaryCompletion":4141,"completion":4141,"start":4142,"enrollment":304,"conditions":4143,"interventions":4145},"NCT05881109","Population Pharmacokinetics and Dose Optimization of Caspofungin in Adolescents",[],"2019-03-03","2018-01-01",[4144],"Invasive Fungal Infections",[4123],{"intervention":3714,"totalTrials":98,"cells":4147},{"EARLY_PHASE1":4148,"PHASE1":4150,"PHASE2":4152,"PHASE3":4154,"PHASE4":4156,"NA":4158},{"trials":4149,"activeCount":102},[],{"trials":4151,"activeCount":102},[],{"trials":4153,"activeCount":102},[],{"trials":4155,"activeCount":102},[],{"trials":4157,"activeCount":102},[],{"trials":4159,"activeCount":102},[4160],{"nctId":3705,"briefTitle":3706,"status":256,"phases":4161,"primaryCompletion":3708,"completion":380,"start":3709,"enrollment":261,"conditions":4162,"interventions":4163},[94],[3711],[3713,3714],{"intervention":4165,"totalTrials":98,"cells":4166},"Serplulimab",{"EARLY_PHASE1":4167,"PHASE1":4169,"PHASE2":4171,"PHASE3":4173,"PHASE4":4175,"NA":4177},{"trials":4168,"activeCount":102},[],{"trials":4170,"activeCount":102},[],{"trials":4172,"activeCount":102},[],{"trials":4174,"activeCount":102},[],{"trials":4176,"activeCount":102},[],{"trials":4178,"activeCount":102},[4179],{"nctId":4180,"briefTitle":4181,"status":256,"phases":4182,"primaryCompletion":4183,"completion":62,"start":4184,"enrollment":333,"conditions":4185,"interventions":4186},"NCT05883670","Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer",[],"2024-03-31","2023-03-09",[726],[4165],{"intervention":4188,"totalTrials":98,"cells":4189},"Amoxicillin + Tetracycline + Bismuth + Esomeprazole",{"EARLY_PHASE1":4190,"PHASE1":4192,"PHASE2":4194,"PHASE3":4196,"PHASE4":4198,"NA":4200},{"trials":4191,"activeCount":102},[],{"trials":4193,"activeCount":102},[],{"trials":4195,"activeCount":102},[],{"trials":4197,"activeCount":102},[],{"trials":4199,"activeCount":102},[],{"trials":4201,"activeCount":102},[4202],{"nctId":4203,"briefTitle":4204,"status":256,"phases":4205,"primaryCompletion":2491,"completion":2491,"start":4206,"enrollment":4207,"conditions":4208,"interventions":4209},"NCT05620589","The Effect of Time Intervals for Rescue Treatment on Eradication Effect of Helicobacter Pylori Infection",[],"2022-11-11",626,[16],[4188,4210,4211],"Amoxicillin + Tetracycline + Bismuth + Vonoprazan","Amoxicillin + Tetracycline + Bismuth + Tegoprazan",{"intervention":4210,"totalTrials":98,"cells":4213},{"EARLY_PHASE1":4214,"PHASE1":4216,"PHASE2":4218,"PHASE3":4220,"PHASE4":4222,"NA":4224},{"trials":4215,"activeCount":102},[],{"trials":4217,"activeCount":102},[],{"trials":4219,"activeCount":102},[],{"trials":4221,"activeCount":102},[],{"trials":4223,"activeCount":102},[],{"trials":4225,"activeCount":102},[4226],{"nctId":4203,"briefTitle":4204,"status":256,"phases":4227,"primaryCompletion":2491,"completion":2491,"start":4206,"enrollment":4207,"conditions":4228,"interventions":4229},[],[16],[4188,4210,4211],{"intervention":4211,"totalTrials":98,"cells":4231},{"EARLY_PHASE1":4232,"PHASE1":4234,"PHASE2":4236,"PHASE3":4238,"PHASE4":4240,"NA":4242},{"trials":4233,"activeCount":102},[],{"trials":4235,"activeCount":102},[],{"trials":4237,"activeCount":102},[],{"trials":4239,"activeCount":102},[],{"trials":4241,"activeCount":102},[],{"trials":4243,"activeCount":102},[4244],{"nctId":4203,"briefTitle":4204,"status":256,"phases":4245,"primaryCompletion":2491,"completion":2491,"start":4206,"enrollment":4207,"conditions":4246,"interventions":4247},[],[16],[4188,4210,4211],{"intervention":4249,"totalTrials":98,"cells":4250},"three kinds of antibiotics",{"EARLY_PHASE1":4251,"PHASE1":4253,"PHASE2":4255,"PHASE3":4257,"PHASE4":4259,"NA":4261},{"trials":4252,"activeCount":102},[],{"trials":4254,"activeCount":102},[],{"trials":4256,"activeCount":102},[],{"trials":4258,"activeCount":102},[],{"trials":4260,"activeCount":102},[],{"trials":4262,"activeCount":102},[4263],{"nctId":4264,"briefTitle":4265,"status":256,"phases":4266,"primaryCompletion":4023,"completion":4023,"start":4267,"enrollment":261,"conditions":4268,"interventions":4269},"NCT05133193","Efficacy and Safety of 14-day Concomitant Therapy for Refractory Helicobacter Pylori Infection",[94],"2021-11-20",[16],[4249],{"intervention":4271,"totalTrials":98,"cells":4272},"bismuth-containing quadral therapy based on antibiotic susceptibility",{"EARLY_PHASE1":4273,"PHASE1":4275,"PHASE2":4277,"PHASE3":4279,"PHASE4":4281,"NA":4283},{"trials":4274,"activeCount":102},[],{"trials":4276,"activeCount":102},[],{"trials":4278,"activeCount":102},[],{"trials":4280,"activeCount":102},[],{"trials":4282,"activeCount":102},[],{"trials":4284,"activeCount":102},[4285],{"nctId":4286,"briefTitle":4287,"status":256,"phases":4288,"primaryCompletion":4289,"completion":4289,"start":293,"enrollment":4290,"conditions":4291,"interventions":4292},"NCT04030715","The Associations Between the Gastric Mucosal Pathology and the Eradication Rate of H.Pylori :A Multicenter Study",[94],"2020-09-30",1200,[27],[4271],{"intervention":4294,"totalTrials":98,"cells":4295},"Amoxicillin,Furazolidone",{"EARLY_PHASE1":4296,"PHASE1":4298,"PHASE2":4300,"PHASE3":4302,"PHASE4":4304,"NA":4306},{"trials":4297,"activeCount":102},[],{"trials":4299,"activeCount":102},[],{"trials":4301,"activeCount":102},[],{"trials":4303,"activeCount":102},[],{"trials":4305,"activeCount":102},[],{"trials":4307,"activeCount":102},[4308],{"nctId":4309,"briefTitle":4310,"status":225,"phases":4311,"primaryCompletion":4312,"completion":4312,"start":4313,"enrollment":4314,"conditions":4315,"interventions":4316},"NCT05173493","The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure",[],"2023-02-10","2021-12-30",670,[16],[4294,4317,4318],"Amoxicillin,Levofloxacin","Tetracycline,Furazolidone",{"intervention":4317,"totalTrials":98,"cells":4320},{"EARLY_PHASE1":4321,"PHASE1":4323,"PHASE2":4325,"PHASE3":4327,"PHASE4":4329,"NA":4331},{"trials":4322,"activeCount":102},[],{"trials":4324,"activeCount":102},[],{"trials":4326,"activeCount":102},[],{"trials":4328,"activeCount":102},[],{"trials":4330,"activeCount":102},[],{"trials":4332,"activeCount":102},[4333],{"nctId":4309,"briefTitle":4310,"status":225,"phases":4334,"primaryCompletion":4312,"completion":4312,"start":4313,"enrollment":4314,"conditions":4335,"interventions":4336},[],[16],[4294,4317,4318],{"intervention":4318,"totalTrials":98,"cells":4338},{"EARLY_PHASE1":4339,"PHASE1":4341,"PHASE2":4343,"PHASE3":4345,"PHASE4":4347,"NA":4349},{"trials":4340,"activeCount":102},[],{"trials":4342,"activeCount":102},[],{"trials":4344,"activeCount":102},[],{"trials":4346,"activeCount":102},[],{"trials":4348,"activeCount":102},[],{"trials":4350,"activeCount":102},[4351],{"nctId":4309,"briefTitle":4310,"status":225,"phases":4352,"primaryCompletion":4312,"completion":4312,"start":4313,"enrollment":4314,"conditions":4353,"interventions":4354},[],[16],[4294,4317,4318],{"intervention":4356,"totalTrials":98,"cells":4357},"propofol",{"EARLY_PHASE1":4358,"PHASE1":4360,"PHASE2":4362,"PHASE3":4364,"PHASE4":4366,"NA":4368},{"trials":4359,"activeCount":102},[],{"trials":4361,"activeCount":102},[],{"trials":4363,"activeCount":102},[],{"trials":4365,"activeCount":102},[],{"trials":4367,"activeCount":102},[],{"trials":4369,"activeCount":102},[4370],{"nctId":4371,"briefTitle":4372,"status":225,"phases":4373,"primaryCompletion":4374,"completion":4374,"start":4375,"enrollment":4376,"conditions":4377,"interventions":4380},"NCT01053871","Propofol Versus Midazolam With Fentanyl for EGD Endomicroscopy",[94],"2010-05","2010-01",104,[4378,4379],"Gastritis","Functional Dyspepsia",[4356,4381],"midazolam with fentanyl",{"intervention":4381,"totalTrials":98,"cells":4383},{"EARLY_PHASE1":4384,"PHASE1":4386,"PHASE2":4388,"PHASE3":4390,"PHASE4":4392,"NA":4394},{"trials":4385,"activeCount":102},[],{"trials":4387,"activeCount":102},[],{"trials":4389,"activeCount":102},[],{"trials":4391,"activeCount":102},[],{"trials":4393,"activeCount":102},[],{"trials":4395,"activeCount":102},[4396],{"nctId":4371,"briefTitle":4372,"status":225,"phases":4397,"primaryCompletion":4374,"completion":4374,"start":4375,"enrollment":4376,"conditions":4398,"interventions":4399},[94],[4378,4379],[4356,4381],{"intervention":4401,"totalTrials":98,"cells":4402},"Tigecycline",{"EARLY_PHASE1":4403,"PHASE1":4405,"PHASE2":4407,"PHASE3":4409,"PHASE4":4411,"NA":4413},{"trials":4404,"activeCount":102},[],{"trials":4406,"activeCount":102},[],{"trials":4408,"activeCount":102},[],{"trials":4410,"activeCount":102},[],{"trials":4412,"activeCount":102},[],{"trials":4414,"activeCount":102},[4415],{"nctId":4416,"briefTitle":4417,"status":256,"phases":4418,"primaryCompletion":3998,"completion":3999,"start":562,"enrollment":118,"conditions":4419,"interventions":4420},"NCT04937894","Antibiotic Therapy for Infectious Diseases",[],[4002],[4401],{"intervention":4422,"totalTrials":98,"cells":4423},"PD-1 inhibitor",{"EARLY_PHASE1":4424,"PHASE1":4426,"PHASE2":4428,"PHASE3":4430,"PHASE4":4432,"NA":4434},{"trials":4425,"activeCount":102},[],{"trials":4427,"activeCount":102},[],{"trials":4429,"activeCount":102},[],{"trials":4431,"activeCount":102},[],{"trials":4433,"activeCount":102},[],{"trials":4435,"activeCount":102},[4436],{"nctId":4437,"briefTitle":4438,"status":256,"phases":4439,"primaryCompletion":4440,"completion":4441,"start":4442,"enrollment":166,"conditions":4443,"interventions":4446},"NCT06448169","Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer",[],"2026-02-28","2026-04-30","2024-05-30",[1357,4444,4445],"Neoadjuvant Immunotherapy","Sensitivity",[4422],{"intervention":4448,"totalTrials":98,"cells":4449},"Bosentan",{"EARLY_PHASE1":4450,"PHASE1":4452,"PHASE2":4454,"PHASE3":4456,"PHASE4":4458,"NA":4460},{"trials":4451,"activeCount":102},[],{"trials":4453,"activeCount":102},[],{"trials":4455,"activeCount":102},[],{"trials":4457,"activeCount":102},[],{"trials":4459,"activeCount":102},[],{"trials":4461,"activeCount":102},[4462],{"nctId":4463,"briefTitle":4464,"status":256,"phases":4465,"primaryCompletion":4466,"completion":1009,"start":4467,"enrollment":879,"conditions":4468,"interventions":4470},"NCT04379180","Population Pharmacokinetics and Dosage Individualization of Oral Pulmonary Vasodilators in PPHN",[],"2023-02-26","2020-04-26",[4469],"Persistent Pulmonary Hypertension of the Newborn",[4448,4471,4472],"Sildenafil","Tadalafil",{"intervention":4471,"totalTrials":98,"cells":4474},{"EARLY_PHASE1":4475,"PHASE1":4477,"PHASE2":4479,"PHASE3":4481,"PHASE4":4483,"NA":4485},{"trials":4476,"activeCount":102},[],{"trials":4478,"activeCount":102},[],{"trials":4480,"activeCount":102},[],{"trials":4482,"activeCount":102},[],{"trials":4484,"activeCount":102},[],{"trials":4486,"activeCount":102},[4487],{"nctId":4463,"briefTitle":4464,"status":256,"phases":4488,"primaryCompletion":4466,"completion":1009,"start":4467,"enrollment":879,"conditions":4489,"interventions":4490},[],[4469],[4448,4471,4472],{"intervention":4472,"totalTrials":98,"cells":4492},{"EARLY_PHASE1":4493,"PHASE1":4495,"PHASE2":4497,"PHASE3":4499,"PHASE4":4501,"NA":4503},{"trials":4494,"activeCount":102},[],{"trials":4496,"activeCount":102},[],{"trials":4498,"activeCount":102},[],{"trials":4500,"activeCount":102},[],{"trials":4502,"activeCount":102},[],{"trials":4504,"activeCount":102},[4505],{"nctId":4463,"briefTitle":4464,"status":256,"phases":4506,"primaryCompletion":4466,"completion":1009,"start":4467,"enrollment":879,"conditions":4507,"interventions":4508},[],[4469],[4448,4471,4472],{"intervention":4510,"totalTrials":98,"cells":4511},"Vonoprazan-Amoxicillin-Tetracycline-Bismuth quadruple regimen for 14 days",{"EARLY_PHASE1":4512,"PHASE1":4514,"PHASE2":4516,"PHASE3":4518,"PHASE4":4520,"NA":4522},{"trials":4513,"activeCount":102},[],{"trials":4515,"activeCount":102},[],{"trials":4517,"activeCount":102},[],{"trials":4519,"activeCount":102},[],{"trials":4521,"activeCount":102},[],{"trials":4523,"activeCount":102},[4524],{"nctId":4525,"briefTitle":4526,"status":256,"phases":4527,"primaryCompletion":52,"completion":186,"start":4528,"enrollment":4529,"conditions":4530,"interventions":4531},"NCT06299605","Triple Versus Quadruple Therapy for the Eradication of Helicobacter Pylori",[94],"2024-11-27",375,[16],[4510,4532,4533],"Vonoprazan-Amoxicillin-Tetracycline triple regimen for 14 days","Vonoprazan-Amoxicillin-Tetracycline triple regimen for 7 days",{"intervention":4532,"totalTrials":98,"cells":4535},{"EARLY_PHASE1":4536,"PHASE1":4538,"PHASE2":4540,"PHASE3":4542,"PHASE4":4544,"NA":4546},{"trials":4537,"activeCount":102},[],{"trials":4539,"activeCount":102},[],{"trials":4541,"activeCount":102},[],{"trials":4543,"activeCount":102},[],{"trials":4545,"activeCount":102},[],{"trials":4547,"activeCount":102},[4548],{"nctId":4525,"briefTitle":4526,"status":256,"phases":4549,"primaryCompletion":52,"completion":186,"start":4528,"enrollment":4529,"conditions":4550,"interventions":4551},[94],[16],[4510,4532,4533],{"intervention":4533,"totalTrials":98,"cells":4553},{"EARLY_PHASE1":4554,"PHASE1":4556,"PHASE2":4558,"PHASE3":4560,"PHASE4":4562,"NA":4564},{"trials":4555,"activeCount":102},[],{"trials":4557,"activeCount":102},[],{"trials":4559,"activeCount":102},[],{"trials":4561,"activeCount":102},[],{"trials":4563,"activeCount":102},[],{"trials":4565,"activeCount":102},[4566],{"nctId":4525,"briefTitle":4526,"status":256,"phases":4567,"primaryCompletion":52,"completion":186,"start":4528,"enrollment":4529,"conditions":4568,"interventions":4569},[94],[16],[4510,4532,4533],{"intervention":4571,"totalTrials":98,"cells":4572},"Amoxicillin,Tetracycline,Furazolidone,Levofloxacin,Vonoprazan fumarate, Esomeprazole ,",{"EARLY_PHASE1":4573,"PHASE1":4575,"PHASE2":4577,"PHASE3":4579,"PHASE4":4581,"NA":4583},{"trials":4574,"activeCount":102},[],{"trials":4576,"activeCount":102},[],{"trials":4578,"activeCount":102},[],{"trials":4580,"activeCount":102},[],{"trials":4582,"activeCount":102},[],{"trials":4584,"activeCount":102},[4585],{"nctId":4586,"briefTitle":2619,"status":256,"phases":4587,"primaryCompletion":4023,"completion":1123,"start":4588,"enrollment":261,"conditions":4589,"interventions":4590},"NCT04991584",[94],"2021-08-04",[16],[4571],{"intervention":4592,"totalTrials":98,"cells":4593},"Puyuanhewei",{"EARLY_PHASE1":4594,"PHASE1":4596,"PHASE2":4598,"PHASE3":4600,"PHASE4":4602,"NA":4604},{"trials":4595,"activeCount":102},[],{"trials":4597,"activeCount":102},[],{"trials":4599,"activeCount":102},[],{"trials":4601,"activeCount":102},[],{"trials":4603,"activeCount":102},[],{"trials":4605,"activeCount":102},[4606],{"nctId":4607,"briefTitle":4608,"status":256,"phases":4609,"primaryCompletion":2579,"completion":2579,"start":340,"enrollment":166,"conditions":4610,"interventions":4612},"NCT02465996","Gastric Barrier Dysfunction of Functional Dyspepsia and Therapeutic Response to Puyuanhewei Detected by Endomicroscopy",[94],[4611],"Dyspepsia",[4592],{"intervention":4614,"totalTrials":98,"cells":4615},"biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc",{"EARLY_PHASE1":4616,"PHASE1":4618,"PHASE2":4620,"PHASE3":4622,"PHASE4":4624,"NA":4626},{"trials":4617,"activeCount":102},[],{"trials":4619,"activeCount":102},[],{"trials":4621,"activeCount":102},[],{"trials":4623,"activeCount":102},[],{"trials":4625,"activeCount":102},[],{"trials":4627,"activeCount":102},[4628],{"nctId":4629,"briefTitle":4630,"status":256,"phases":4631,"primaryCompletion":4632,"completion":1010,"start":4633,"enrollment":879,"conditions":4634,"interventions":4636},"NCT04799626","Population Pharmacokinetics and Dosage Individualization of Antibiotics in Elderly Patients",[],"2023-03-30","2021-04-01",[4635],"Elderly Infection",[4614],{"intervention":4638,"totalTrials":98,"cells":4639},"Propafenone and Propranolol",{"EARLY_PHASE1":4640,"PHASE1":4642,"PHASE2":4644,"PHASE3":4646,"PHASE4":4648,"NA":4650},{"trials":4641,"activeCount":102},[],{"trials":4643,"activeCount":102},[],{"trials":4645,"activeCount":102},[],{"trials":4647,"activeCount":102},[],{"trials":4649,"activeCount":102},[],{"trials":4651,"activeCount":102},[4652],{"nctId":4653,"briefTitle":4654,"status":256,"phases":4655,"primaryCompletion":4656,"completion":3999,"start":4657,"enrollment":879,"conditions":4658,"interventions":4660},"NCT05463614","Population Pharmacokinetics of Propafenone and Propranolol in Children Patients",[],"2022-08-01","2019-02-01",[4659],"Arrhythmia",[4638],{"intervention":4662,"totalTrials":98,"cells":4663},"Erzhi Tiangui Granule",{"EARLY_PHASE1":4664,"PHASE1":4666,"PHASE2":4668,"PHASE3":4670,"PHASE4":4672,"NA":4674},{"trials":4665,"activeCount":102},[],{"trials":4667,"activeCount":102},[],{"trials":4669,"activeCount":102},[],{"trials":4671,"activeCount":102},[],{"trials":4673,"activeCount":102},[],{"trials":4675,"activeCount":102},[4676],{"nctId":4677,"briefTitle":4678,"status":225,"phases":4679,"primaryCompletion":4680,"completion":62,"start":3138,"enrollment":2320,"conditions":4681,"interventions":4682},"NCT05698550","The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET",[94],"2025-06-30",[144],[4662,4683],"Erzhi Tiangui Placebo",{"intervention":4683,"totalTrials":98,"cells":4685},{"EARLY_PHASE1":4686,"PHASE1":4688,"PHASE2":4690,"PHASE3":4692,"PHASE4":4694,"NA":4696},{"trials":4687,"activeCount":102},[],{"trials":4689,"activeCount":102},[],{"trials":4691,"activeCount":102},[],{"trials":4693,"activeCount":102},[],{"trials":4695,"activeCount":102},[],{"trials":4697,"activeCount":102},[4698],{"nctId":4677,"briefTitle":4678,"status":225,"phases":4699,"primaryCompletion":4680,"completion":62,"start":3138,"enrollment":2320,"conditions":4700,"interventions":4701},[94],[144],[4662,4683],{"intervention":4703,"totalTrials":98,"cells":4704},"2L Polyethylene Glycol",{"EARLY_PHASE1":4705,"PHASE1":4707,"PHASE2":4709,"PHASE3":4711,"PHASE4":4713,"NA":4715},{"trials":4706,"activeCount":102},[],{"trials":4708,"activeCount":102},[],{"trials":4710,"activeCount":102},[],{"trials":4712,"activeCount":102},[],{"trials":4714,"activeCount":102},[],{"trials":4716,"activeCount":102},[4717],{"nctId":4718,"briefTitle":4719,"status":256,"phases":4720,"primaryCompletion":4721,"completion":2622,"start":1421,"enrollment":2276,"conditions":4722,"interventions":4723},"NCT03765216","Efficacy of Tailored Bowel Preparation Strategy: A Randomized Controlled Study",[94],"2019-02-28",[36,3702],[4703,4724],"4L Polyethylene Glycol",{"intervention":4724,"totalTrials":98,"cells":4726},{"EARLY_PHASE1":4727,"PHASE1":4729,"PHASE2":4731,"PHASE3":4733,"PHASE4":4735,"NA":4737},{"trials":4728,"activeCount":102},[],{"trials":4730,"activeCount":102},[],{"trials":4732,"activeCount":102},[],{"trials":4734,"activeCount":102},[],{"trials":4736,"activeCount":102},[],{"trials":4738,"activeCount":102},[4739],{"nctId":4718,"briefTitle":4719,"status":256,"phases":4740,"primaryCompletion":4721,"completion":2622,"start":1421,"enrollment":2276,"conditions":4741,"interventions":4742},[94],[36,3702],[4703,4724],{"intervention":4744,"totalTrials":98,"cells":4745},"Paracetamol",{"EARLY_PHASE1":4746,"PHASE1":4748,"PHASE2":4750,"PHASE3":4752,"PHASE4":4754,"NA":4756},{"trials":4747,"activeCount":102},[],{"trials":4749,"activeCount":102},[],{"trials":4751,"activeCount":102},[],{"trials":4753,"activeCount":102},[],{"trials":4755,"activeCount":102},[],{"trials":4757,"activeCount":102},[4758],{"nctId":4759,"briefTitle":4760,"status":256,"phases":4761,"primaryCompletion":4762,"completion":4763,"start":4764,"enrollment":879,"conditions":4765,"interventions":4767},"NCT04397913","Population Pharmacokinetics and Dosage Individualization of Paracetamol and Ibuprofen in Children With PDA",[],"2023-01-30","2023-05-06","2020-05-25",[4766],"Patent Ductus Arteriosus",[4744,4768],"Ibuprofen",{"intervention":4768,"totalTrials":98,"cells":4770},{"EARLY_PHASE1":4771,"PHASE1":4773,"PHASE2":4775,"PHASE3":4777,"PHASE4":4779,"NA":4781},{"trials":4772,"activeCount":102},[],{"trials":4774,"activeCount":102},[],{"trials":4776,"activeCount":102},[],{"trials":4778,"activeCount":102},[],{"trials":4780,"activeCount":102},[],{"trials":4782,"activeCount":102},[4783],{"nctId":4759,"briefTitle":4760,"status":256,"phases":4784,"primaryCompletion":4762,"completion":4763,"start":4764,"enrollment":879,"conditions":4785,"interventions":4786},[],[4766],[4744,4768],{"intervention":4788,"totalTrials":98,"cells":4789},"Piperacillin and tazobactam, azlocillin, latamoxef, meropenem, vancomycin，cefotaxime",{"EARLY_PHASE1":4790,"PHASE1":4792,"PHASE2":4794,"PHASE3":4796,"PHASE4":4798,"NA":4800},{"trials":4791,"activeCount":102},[],{"trials":4793,"activeCount":102},[],{"trials":4795,"activeCount":102},[],{"trials":4797,"activeCount":102},[],{"trials":4799,"activeCount":102},[],{"trials":4801,"activeCount":102},[4802],{"nctId":4803,"briefTitle":4804,"status":256,"phases":4805,"primaryCompletion":1354,"completion":57,"start":4806,"enrollment":879,"conditions":4807,"interventions":4809},"NCT03932123","Antibiotic Therapy for Early Onset Neonatal Sepsis",[],"2019-05-05",[4808],"Early Onset Neonatal Sepsis",[4788],{"intervention":3751,"totalTrials":98,"cells":4811},{"EARLY_PHASE1":4812,"PHASE1":4814,"PHASE2":4816,"PHASE3":4818,"PHASE4":4820,"NA":4822},{"trials":4813,"activeCount":102},[],{"trials":4815,"activeCount":102},[],{"trials":4817,"activeCount":102},[],{"trials":4819,"activeCount":102},[],{"trials":4821,"activeCount":102},[],{"trials":4823,"activeCount":102},[4824],{"nctId":3743,"briefTitle":3744,"status":256,"phases":4825,"primaryCompletion":433,"completion":3746,"start":3747,"enrollment":1161,"conditions":4826,"interventions":4827},[94],[3749],[3751,3510],{"intervention":4829,"totalTrials":98,"cells":4830},"Teicoplanin-PMMA",{"EARLY_PHASE1":4831,"PHASE1":4833,"PHASE2":4835,"PHASE3":4837,"PHASE4":4839,"NA":4841},{"trials":4832,"activeCount":102},[],{"trials":4834,"activeCount":102},[],{"trials":4836,"activeCount":102},[],{"trials":4838,"activeCount":102},[],{"trials":4840,"activeCount":102},[],{"trials":4842,"activeCount":102},[4843],{"nctId":4844,"briefTitle":4845,"status":256,"phases":4846,"primaryCompletion":4847,"completion":57,"start":1399,"enrollment":879,"conditions":4848,"interventions":4850},"NCT03933748","Therapeutic Drug Monitoring of Teicoplanin in Children",[],"2025-11",[4849],"Bacterial Infections",[4829],{"intervention":4852,"totalTrials":98,"cells":4853},"hFSH（Fostimon）",{"EARLY_PHASE1":4854,"PHASE1":4856,"PHASE2":4858,"PHASE3":4860,"PHASE4":4862,"NA":4864},{"trials":4855,"activeCount":102},[],{"trials":4857,"activeCount":102},[],{"trials":4859,"activeCount":102},[],{"trials":4861,"activeCount":102},[],{"trials":4863,"activeCount":102},[],{"trials":4865,"activeCount":102},[4866],{"nctId":4867,"briefTitle":4868,"status":256,"phases":4869,"primaryCompletion":4870,"completion":4870,"start":4871,"enrollment":4872,"conditions":4873,"interventions":4875},"NCT01107470","Age-related Variability of the Efficacy and Tolerability of Alternative Pituitary Suppression Regimens in ART",[],"2013-04","2010-04",2000,[4874],"Infertility",[4852,4852,4852,4852],{"intervention":4877,"totalTrials":98,"cells":4878},"AHCC®capsules",{"EARLY_PHASE1":4879,"PHASE1":4881,"PHASE2":4883,"PHASE3":4885,"PHASE4":4887,"NA":4889},{"trials":4880,"activeCount":102},[],{"trials":4882,"activeCount":102},[],{"trials":4884,"activeCount":102},[],{"trials":4886,"activeCount":102},[],{"trials":4888,"activeCount":102},[],{"trials":4890,"activeCount":102},[4891],{"nctId":4892,"briefTitle":4893,"status":256,"phases":4894,"primaryCompletion":4895,"completion":2491,"start":4896,"enrollment":261,"conditions":4897,"interventions":4900},"NCT04633330","Evaluation of AHCC® for the Clearance of High Risk-HPV Infections in Chinese Female",[94],"2024-06-30","2020-10-26",[4898,4899],"High Risk Human Papillomavirus Infection","Low Grade Squamous Intraepithelial Lesion",[4877,4901],"Simulation of AHCC®capsules",{"intervention":4901,"totalTrials":98,"cells":4903},{"EARLY_PHASE1":4904,"PHASE1":4906,"PHASE2":4908,"PHASE3":4910,"PHASE4":4912,"NA":4914},{"trials":4905,"activeCount":102},[],{"trials":4907,"activeCount":102},[],{"trials":4909,"activeCount":102},[],{"trials":4911,"activeCount":102},[],{"trials":4913,"activeCount":102},[],{"trials":4915,"activeCount":102},[4916],{"nctId":4892,"briefTitle":4893,"status":256,"phases":4917,"primaryCompletion":4895,"completion":2491,"start":4896,"enrollment":261,"conditions":4918,"interventions":4919},[94],[4898,4899],[4877,4901]]